"","MUTATION_ID","VIRUS","GENOTYPE","GENE","AA","REF_REV","REF_TITLE","REF_LINK","REF_DOI","TM","TM_GROUP","TM_CLASS","test.type....in.vitro..hypothesised..clinical.isolate..in.silico.prediction.","co.gene","co.AA","Created_date","Created_by","note","Status","variable","value"
"1","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.6"
"2","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.3"
"3","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.9"
"4","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.2"
"5","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.1"
"6","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.9"
"7","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.2"
"8","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.6"
"9","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.3"
"10","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.3"
"11","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6.5"
"12","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.8"
"13","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.8"
"14","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.5"
"15","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.1"
"16","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.2"
"17","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6"
"18","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.9"
"19","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.8"
"20","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5"
"21","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6"
"22","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","GCV","9.8"
"23","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.7"
"24","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.7"
"25","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","1"
"26","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.6"
"27","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.1"
"28","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.1"
"29","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","GCV","3"
"30","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3"
"31","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","GCV","1.3"
"32","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.1"
"33","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.5"
"34","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.5"
"35","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.1"
"36","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.2"
"37","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.5"
"38","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GCV","1"
"39","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.5"
"40","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.9"
"41","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.9"
"42","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.3"
"43","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.5"
"44","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.3"
"45","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GCV","2"
"46","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.8"
"47","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.3"
"48","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","1.6"
"49","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.2"
"50","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","GCV","0.9"
"51","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","0.8"
"52","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.3"
"53","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","GCV","1"
"54","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.9"
"55","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.2"
"56","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.5"
"57","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.7"
"58","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3"
"59","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"60","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1"
"61","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"62","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.4"
"63","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.1"
"64","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.8"
"65","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1"
"66","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.6"
"67","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV",""
"68","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"69","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"70","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","4.5"
"71","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2"
"72","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","GCV","5.4"
"73","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","GCV","22.7"
"74","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.8"
"75","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.2"
"76","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.4"
"77","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"78","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.7"
"79","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.1"
"80","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.7"
"81","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","1.4"
"82","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","8.3"
"83","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","5.1"
"84","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.3"
"85","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","GCV","1.1"
"86","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","GCV","1.5"
"87","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","GCV","6.2"
"88","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","GCV","6.6"
"89","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","GCV","4.3"
"90","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","5"
"91","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","2.6"
"92","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"93","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","GCV","7.3"
"94","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","4"
"95","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","GCV","4.2"
"96","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","GCV","4.9"
"97","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","GCV","1.6"
"98","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.3"
"99","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.7"
"100","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.3"
"101","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","GCV","2.4"
"102","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.8"
"103","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GCV","4.8"
"104","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GCV","7.4"
"105","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","GCV","16"
"106","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GCV","3.2"
"107","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","GCV","1.1"
"108","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","GCV","6.1"
"109","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"110","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"111","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.1"
"112","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"113","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"114","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"115","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.4"
"116","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.3"
"117","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"118","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"119","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.9"
"120","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"121","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"122","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.1"
"123","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"124","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"125","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"126","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.8"
"127","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","2"
"128","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"129","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"130","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"131","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","2.2"
"132","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.8"
"133","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"134","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.1"
"135","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1"
"136","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"137","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.2"
"138","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","0.9"
"139","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GCV","1.9"
"140","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","GCV","2 - 4"
"141","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","GCV","r"
"142","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","7.8"
"143","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","16"
"144","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.5"
"145","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.5"
"146","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","12"
"147","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5"
"148","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","9.3"
"149","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","8.3"
"150","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.5"
"151","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","9"
"152","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","12"
"153","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","10"
"154","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","17"
"155","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6"
"156","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6.3"
"157","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"158","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.3"
"159","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6.2"
"160","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","31.5"
"161","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.9"
"162","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3"
"163","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","13.5"
"164","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.9"
"165","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.7"
"166","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","8.3"
"167","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","15.7"
"168","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","9.2"
"169","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.1"
"170","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","13.3"
"171","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","8.4"
"172","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"173","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.3"
"174","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","6.4"
"175","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"176","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"177","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.3"
"178","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.9"
"179","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","11"
"180","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","3.6-8.3"
"181","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.9"
"182","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","8"
"183","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.9"
"184","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","12.5"
"185","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.8"
"186","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","2.3"
"187","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","10"
"188","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.7"
"189","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"190","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"191","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"192","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"193","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"194","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"195","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"196","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"197","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"198","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"199","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"200","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"201","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"202","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"203","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"204","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"205","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"206","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"207","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"208","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"209","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"210","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"211","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","GCV",""
"212","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"213","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"214","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"215","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"216","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","GCV",""
"217","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"218","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","7.3"
"219","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"220","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV",""
"221","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"222","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"223","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"224","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"225","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"226","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"227","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"228","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"229","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"230","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"231","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"232","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"233","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"234","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"235","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"236","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"237","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"238","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"239","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"240","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"241","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"242","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"243","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"244","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"245","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"246","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"247","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"248","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"249","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"250","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"251","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"252","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","GCV",""
"253","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","GCV",""
"254","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","GCV",""
"255","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","GCV",""
"256","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","GCV",""
"257","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","GCV",""
"258","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"259","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"260","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"261","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"262","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"263","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"264","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"265","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"266","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"267","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","GCV",""
"268","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","GCV",""
"269","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","GCV",""
"270","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","GCV",""
"271","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GCV",""
"272","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1"
"273","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","7.8"
"274","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1"
"275","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","16"
"276","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","5.5"
"277","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1.6"
"278","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","0.9"
"279","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","0.7"
"280","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","1"
"281","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","0.5"
"282","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","12"
"283","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","11"
"284","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","9"
"285","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","17"
"286","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV","10"
"287","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","GCV","1"
"288","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","GCV","0.7"
"289","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"290","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"291","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"292","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"293","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"294","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"295","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"296","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"297","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"298","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"299","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"300","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GCV",""
"301","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","GCV",""
"302","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","GCV",""
"303","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","GCV",""
"304","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GCV","R"
"305","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GCV","R"
"306","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GCV","R"
"307","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","GCV","R"
"308","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV","6"
"309","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","3"
"310","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV",""
"311","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV",""
"312","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV","3.8"
"313","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV","3.7"
"314","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","GCV","5.9"
"315","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"316","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"317","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"318","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"319","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"320","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"321","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","R"
"322","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV",""
"323","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"324","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"325","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"326","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"327","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"328","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"329","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"330","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"331","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"332","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"333","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","<2"
"334","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"335","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"336","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"337","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"338","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"339","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","2-5"
"340","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","5-15"
"341","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GCV","5-15"
"342","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","GCV","R"
"343","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","GCV","R"
"344","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GCV","1"
"345","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GCV","0.4"
"346","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GCV","0.4"
"347","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GCV","0.8"
"348","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","GCV",""
"349","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"350","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"351","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"352","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"353","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"354","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"355","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"356","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"357","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"358","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"359","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"360","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"361","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"362","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"363","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"364","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"365","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"366","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"367","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"368","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"369","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"370","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"371","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"372","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"373","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"374","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"375","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"376","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"377","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"378","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"379","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"380","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"381","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"382","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"383","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"384","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"385","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"386","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"387","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"388","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"389","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"390","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"391","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"392","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"393","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"394","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"395","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"396","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"397","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"398","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"399","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"400","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"401","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"402","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"403","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"404","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","GCV","2.9"
"405","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV","8.5"
"406","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GCV","3.2"
"407","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"408","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV",""
"409","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"410","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"411","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"412","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"413","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"414","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"415","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"416","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"417","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"418","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"419","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GCV","R"
"420","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","7.8"
"421","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","9.3"
"422","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","8.3"
"423","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","7.8"
"424","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","3"
"425","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","8.6"
"426","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","8.5"
"427","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","8.3"
"428","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","1.9"
"429","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","7.9"
"430","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","3.2"
"431","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","4.4"
"432","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","7"
"433","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","GCV",""
"434","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","GCV",""
"435","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","GCV","4.7"
"436","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.7"
"437","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.1"
"438","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.3"
"439","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","GCV","1.7"
"440","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.8"
"441","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.8"
"442","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.5"
"443","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GCV","1.8"
"444","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GCV","1"
"445","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GCV","2"
"446","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GCV","2"
"447","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GCV","10"
"448","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GCV","S"
"449","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"450","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"451","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"452","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"453","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"454","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"455","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"456","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"457","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"458","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"459","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"460","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"461","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"462","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"463","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"464","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"465","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"466","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"467","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"468","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"469","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"470","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"471","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"472","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"473","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"474","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"475","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"476","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"477","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"478","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"479","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"480","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"481","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"482","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"483","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"484","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"485","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GCV","S"
"486","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"487","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"488","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"489","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"490","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"491","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"492","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"493","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"494","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"495","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"496","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"497","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"498","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"499","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"500","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"501","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"502","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"503","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"504","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"505","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"506","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"507","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"508","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"509","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"510","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"511","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"512","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"513","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"514","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"515","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"516","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"517","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"518","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"519","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"520","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"521","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"522","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"523","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"524","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"525","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"526","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"527","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"528","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"529","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"530","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"531","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"532","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"533","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"534","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"535","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"536","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"537","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"538","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"539","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"540","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"541","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"542","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"543","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"544","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"545","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"546","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GCV","S"
"547","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","1.1"
"548","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","1.3"
"549","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GCV","2"
"550","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","3"
"551","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.4"
"552","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","5.6"
"553","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","21"
"554","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","7.5"
"555","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","3"
"556","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","18"
"557","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","9.4"
"558","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","13"
"559","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","15.5"
"560","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","11"
"561","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","4.3"
"562","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","10"
"563","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","7.9"
"564","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.1"
"565","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","3"
"566","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","9.1"
"567","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","6.1"
"568","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2"
"569","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","9.1"
"570","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","12.5"
"571","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","CDV","34"
"572","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","10"
"573","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"574","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","1"
"575","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"576","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","5.1"
"577","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","5.1"
"578","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","CDV","3.9"
"579","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","4.1"
"580","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","CDV","1.2"
"581","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","3.6"
"582","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","9.7"
"583","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.5"
"584","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","4.4"
"585","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","13.3"
"586","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","12"
"587","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.1"
"588","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","9.1"
"589","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","6.3"
"590","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.2"
"591","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.3"
"592","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.4"
"593","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.1"
"594","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.3"
"595","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.7"
"596","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.2"
"597","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","1.7"
"598","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.3"
"599","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","CDV","1.5"
"600","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.7"
"601","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.1"
"602","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","CDV","1.1"
"603","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.9"
"604","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.7"
"605","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.2"
"606","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1"
"607","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.5"
"608","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1"
"609","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.2"
"610","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"611","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1"
"612","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.9"
"613","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.1"
"614","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.2"
"615","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.7"
"616","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV",""
"617","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","3.2"
"618","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.7"
"619","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.9"
"620","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.6"
"621","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","CDV","3"
"622","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","CDV","18.8"
"623","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.8"
"624","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.6"
"625","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.3"
"626","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.6"
"627","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.9"
"628","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","0.9"
"629","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","1.4"
"630","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","1"
"631","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","2.8"
"632","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","4.5"
"633","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","11.3"
"634","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","CDV","1.2"
"635","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","CDV","1.1"
"636","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","CDV","16"
"637","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","CDV","11.1"
"638","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","CDV","2.1"
"639","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","11.9"
"640","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","2"
"641","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"642","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","CDV","4.5"
"643","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","4.2"
"644","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","CDV","1.9"
"645","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","CDV","4.5"
"646","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","CDV","0.9"
"647","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.8"
"648","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"649","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.1"
"650","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","CDV","2.4"
"651","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"652","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"653","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","CDV","16"
"654","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","CDV","6.5"
"655","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","CDV","2.1"
"656","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","CDV","2"
"657","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","CDV","6"
"658","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"659","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"660","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"661","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.7"
"662","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.1"
"663","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.2"
"664","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"665","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.3"
"666","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"667","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.2"
"668","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.9"
"669","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"670","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"671","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.1"
"672","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"673","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"674","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.8"
"675","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"676","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.7"
"677","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.7"
"678","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"679","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"680","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1.1"
"681","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"682","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"683","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"684","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","1"
"685","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.9"
"686","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.7"
"687","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.8"
"688","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","CDV","0.8"
"689","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","CDV",""
"690","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","CDV",""
"691","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"692","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"693","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"694","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"695","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"696","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"697","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"698","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"699","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"700","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"701","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"702","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"703","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"704","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"705","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"706","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"707","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"708","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"709","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"710","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"711","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"712","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"713","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"714","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"715","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"716","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"717","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"718","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"719","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"720","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"721","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"722","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"723","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"724","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"725","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"726","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"727","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"728","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"729","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"730","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"731","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"732","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"733","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"734","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"735","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"736","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"737","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"738","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"739","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"740","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"741","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"742","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"743","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"744","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"745","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"746","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"747","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"748","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"749","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"750","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"751","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"752","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"753","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"754","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"755","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"756","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"757","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"758","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"759","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"760","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","CDV",""
"761","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"762","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"763","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"764","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"765","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","CDV",""
"766","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"767","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","3.8"
"768","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"769","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV",""
"770","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"771","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"772","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"773","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"774","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"775","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"776","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"777","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"778","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"779","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"780","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"781","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"782","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"783","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"784","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"785","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"786","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"787","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"788","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"789","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"790","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"791","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"792","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"793","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"794","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"795","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"796","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"797","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"798","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"799","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"800","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"801","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","CDV",""
"802","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","CDV",""
"803","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","CDV",""
"804","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","CDV",""
"805","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","CDV",""
"806","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","CDV",""
"807","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"808","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"809","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"810","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"811","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"812","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"813","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"814","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"815","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"816","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","CDV",""
"817","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","CDV",""
"818","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","CDV",""
"819","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","CDV",""
"820","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","CDV",""
"821","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"822","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","17"
"823","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"824","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","23"
"825","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","7"
"826","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"827","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"828","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"829","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"830","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"831","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"832","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","17"
"833","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"834","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV","20"
"835","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"836","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","CDV",""
"837","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","CDV",""
"838","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"839","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"840","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"841","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"842","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"843","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"844","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"845","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"846","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"847","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"848","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"849","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","CDV",""
"850","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","CDV",""
"851","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","CDV",""
"852","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","CDV",""
"853","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","CDV",""
"854","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","CDV",""
"855","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","CDV",""
"856","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","CDV",""
"857","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV",""
"858","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV",""
"859","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV",""
"860","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV",""
"861","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV",""
"862","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV",""
"863","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","CDV",""
"864","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"865","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV","R"
"866","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV","R"
"867","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV","R"
"868","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV","R"
"869","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"870","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV","R"
"871","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"872","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"873","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"874","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"875","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"876","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"877","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"878","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"879","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"880","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"881","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"882","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"883","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"884","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"885","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"886","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"887","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"888","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"889","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"890","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","CDV",""
"891","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","CDV",""
"892","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","CDV","R"
"893","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","CDV","1.9"
"894","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","CDV","0.3"
"895","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","CDV","0.3"
"896","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","CDV","0.2"
"897","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","CDV",""
"898","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"899","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"900","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"901","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"902","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"903","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"904","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"905","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"906","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"907","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"908","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"909","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"910","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"911","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"912","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"913","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"914","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"915","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"916","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"917","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"918","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"919","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"920","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"921","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"922","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"923","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"924","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"925","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"926","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"927","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"928","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"929","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"930","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"931","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"932","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"933","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"934","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"935","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"936","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"937","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"938","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"939","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"940","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"941","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"942","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"943","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"944","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"945","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"946","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"947","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"948","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"949","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"950","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"951","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"952","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"953","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","CDV","1.3"
"954","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV","2.9"
"955","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","CDV","1.8"
"956","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV","R"
"957","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV","R"
"958","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"959","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"960","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"961","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"962","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV","R"
"963","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"964","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"965","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"966","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"967","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV","R"
"968","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","CDV",""
"969","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"970","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"971","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"972","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"973","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"974","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"975","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"976","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"977","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"978","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"979","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV","2.6"
"980","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV","5.9"
"981","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","3.2"
"982","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","CDV",""
"983","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","CDV",""
"984","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","CDV","16"
"985","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.4"
"986","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1"
"987","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1"
"988","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","CDV","1.2"
"989","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1"
"990","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","0.9"
"991","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.1"
"992","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","CDV","1.2"
"993","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","CDV",""
"994","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","CDV",""
"995","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","CDV",""
"996","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","CDV",""
"997","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","CDV",""
"998","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"999","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1000","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1001","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1002","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1003","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1004","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1005","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1006","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1007","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1008","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1009","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1010","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1011","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1012","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1013","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1014","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1015","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1016","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1017","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1018","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1019","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1020","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1021","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1022","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1023","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1024","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1025","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1026","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1027","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1028","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1029","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1030","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1031","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1032","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1033","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1034","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","CDV",""
"1035","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1036","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1037","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1038","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1039","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1040","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1041","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1042","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1043","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1044","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1045","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1046","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1047","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1048","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1049","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1050","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1051","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1052","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1053","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1054","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1055","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1056","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1057","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1058","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1059","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1060","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1061","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1062","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1063","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1064","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1065","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1066","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1067","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1068","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1069","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1070","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1071","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1072","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1073","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1074","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1075","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1076","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1077","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1078","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1079","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1080","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1081","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1082","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1083","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1084","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1085","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1086","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1087","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1088","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1089","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1090","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1091","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1092","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1093","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1094","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1095","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","CDV",""
"1096","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","0.9"
"1097","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","1.5"
"1098","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","CDV","0.8"
"1099","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.5"
"1100","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1101","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.3"
"1102","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.7"
"1103","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1"
"1104","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1105","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.2"
"1106","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1107","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1108","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1109","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1110","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1111","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1"
"1112","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.6"
"1113","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.4"
"1114","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.2"
"1115","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.4"
"1116","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.5"
"1117","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1118","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.4"
"1119","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.5"
"1120","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","FOS","3"
"1121","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1122","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.6"
"1123","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1124","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.6"
"1125","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1126","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1127","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","FOS","1"
"1128","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1"
"1129","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","FOS","1.4"
"1130","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1131","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1132","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.8"
"1133","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1"
"1134","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.7"
"1135","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.7"
"1136","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1137","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.2"
"1138","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.3"
"1139","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.6"
"1140","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.5"
"1141","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.7"
"1142","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.3"
"1143","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","FOS","2.8"
"1144","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.2,9"
"1145","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2"
"1146","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","3.3"
"1147","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","5.8"
"1148","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","FOS","4.7"
"1149","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.8"
"1150","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","9.5"
"1151","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","FOS","5.5"
"1152","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.2"
"1153","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.4"
"1154","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",">8"
"1155","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.3"
"1156","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.4"
"1157","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.5"
"1158","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","5.2"
"1159","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.5"
"1160","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.1"
"1161","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.2"
"1162","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.9"
"1163","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","0.18"
"1164","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","6.3"
"1165","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","3.6"
"1166","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.9"
"1167","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.9"
"1168","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","21"
"1169","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1170","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","FOS","6.4"
"1171","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","FOS","7.2"
"1172","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.4"
"1173","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","4.3"
"1174","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.5"
"1175","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.2"
"1176","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.1"
"1177","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","2.4"
"1178","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.3"
"1179","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1180","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","3.6"
"1181","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS",""
"1182","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS","1.2"
"1183","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","FOS","0.9"
"1184","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","FOS","1.1"
"1185","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","FOS","3.1"
"1186","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","FOS","2.7"
"1187","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","FOS","10.1"
"1188","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1189","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.8"
"1190","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1191","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","FOS","1.8"
"1192","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.3"
"1193","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","FOS","4"
"1194","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","FOS","3.3"
"1195","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","FOS","5.5"
"1196","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.3"
"1197","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","2.7"
"1198","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1199","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","FOS","2.7"
"1200","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","2.4"
"1201","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","FOS",""
"1202","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","FOS","1.5"
"1203","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","FOS","1.3"
"1204","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","FOS","5.8"
"1205","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","FOS","1"
"1206","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","FOS","7.7"
"1207","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1208","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.3"
"1209","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1210","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1211","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1212","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1213","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1214","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1215","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.8"
"1216","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1217","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1218","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1219","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.7"
"1220","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1221","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1222","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.8"
"1223","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1224","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1225","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1226","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1227","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1228","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1229","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","2.1"
"1230","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.8"
"1231","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1"
"1232","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1233","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1234","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","1.2"
"1235","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.9"
"1236","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","0.4"
"1237","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","FOS","3"
"1238","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","FOS",""
"1239","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","FOS",""
"1240","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1241","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1242","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1243","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1244","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1245","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1246","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1247","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1248","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1249","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1250","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1251","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1252","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1253","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1254","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1255","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1256","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1257","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1258","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1259","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1260","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1261","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1262","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1263","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1264","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1265","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1266","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1267","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1268","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1269","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1270","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1271","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1272","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1273","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1274","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1275","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1276","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1277","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1278","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1279","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1280","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1281","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1282","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1283","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1284","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1285","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1286","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1287","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1288","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1289","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1290","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1291","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1292","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1293","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1294","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1295","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1296","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1297","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1298","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1299","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1300","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1301","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1302","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1303","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1304","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1305","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1306","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1307","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1308","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1309","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","FOS",""
"1310","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1311","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1312","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1313","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1314","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","FOS",""
"1315","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1316","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","3.1"
"1317","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1318","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS",""
"1319","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1320","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1321","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1322","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1323","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1324","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1325","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1326","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1327","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1328","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1329","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1330","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1331","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1332","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1333","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1334","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1335","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1336","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1337","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1338","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1339","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1340","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1341","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1342","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1343","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1344","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1345","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1346","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1347","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1348","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1349","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1350","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","FOS",""
"1351","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","FOS",""
"1352","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","FOS",""
"1353","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","FOS",""
"1354","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","FOS",""
"1355","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","FOS",""
"1356","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1357","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1358","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1359","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1360","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1361","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1362","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1363","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1364","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1365","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","FOS",""
"1366","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","FOS",""
"1367","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","FOS",""
"1368","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","FOS",""
"1369","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","FOS",""
"1370","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1371","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1372","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1373","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1374","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1375","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1376","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1377","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1378","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1379","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1380","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1381","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1382","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1383","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1384","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1385","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","FOS",""
"1386","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","FOS",""
"1387","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1388","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1389","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1390","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1391","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1392","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1393","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1394","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1395","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1396","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1397","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1398","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","FOS",""
"1399","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","FOS",""
"1400","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","FOS",""
"1401","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","FOS",""
"1402","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","FOS","R"
"1403","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","FOS","R"
"1404","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","FOS","R"
"1405","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","FOS",""
"1406","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1407","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS",""
"1408","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS",""
"1409","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1410","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1411","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1412","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","FOS",""
"1413","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS","R"
"1414","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1415","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1416","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1417","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1418","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS","R"
"1419","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1420","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS","R"
"1421","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1422","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1423","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1424","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1425","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1426","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1427","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1428","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1429","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1430","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1431","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1432","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1433","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1434","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1435","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1436","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1437","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1438","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1439","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","FOS",""
"1440","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","FOS",""
"1441","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","FOS",""
"1442","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1443","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","FOS","0.4"
"1444","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","FOS","0.4"
"1445","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","FOS","0.4"
"1446","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","FOS",""
"1447","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1448","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1449","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1450","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1451","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1452","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1453","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1454","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1455","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1456","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1457","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1458","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1459","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1460","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1461","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1462","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1463","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1464","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1465","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1466","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1467","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1468","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1469","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1470","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1471","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1472","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1473","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1474","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1475","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1476","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1477","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1478","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1479","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1480","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1481","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1482","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1483","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1484","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1485","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1486","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1487","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1488","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1489","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1490","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1491","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1492","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1493","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1494","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1495","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1496","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1497","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1498","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1499","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1500","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1501","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1502","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","FOS","5.25"
"1503","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS","3.4"
"1504","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","FOS","9.4"
"1505","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1506","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1507","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1508","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1509","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1510","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1511","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1512","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1513","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1514","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1515","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1516","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1517","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","FOS",""
"1518","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1519","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1520","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1521","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1522","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1523","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1524","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1525","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1526","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1527","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1528","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1529","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1530","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","2.7"
"1531","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","FOS","R"
"1532","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","FOS","R"
"1533","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","FOS","0.6"
"1534","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","2.3"
"1535","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","1.1"
"1536","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","2.6"
"1537","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","FOS","3.5"
"1538","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","2.5"
"1539","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","1.7"
"1540","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","1.7"
"1541","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","FOS","3.9"
"1542","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","FOS","8"
"1543","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","FOS","10"
"1544","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","FOS","5"
"1545","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","FOS","1"
"1546","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","FOS",""
"1547","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1548","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1549","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1550","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1551","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1552","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1553","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1554","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1555","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1556","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1557","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1558","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1559","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1560","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1561","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1562","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1563","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1564","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1565","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1566","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1567","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1568","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1569","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1570","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1571","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1572","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1573","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1574","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1575","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1576","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1577","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1578","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1579","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1580","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1581","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1582","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1583","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","FOS",""
"1584","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1585","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1586","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1587","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1588","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1589","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1590","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1591","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1592","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1593","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1594","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1595","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1596","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1597","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1598","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1599","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1600","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1601","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1602","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1603","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1604","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1605","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1606","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1607","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1608","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1609","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1610","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1611","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1612","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1613","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1614","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1615","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1616","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1617","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1618","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1619","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1620","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1621","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1622","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1623","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1624","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1625","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1626","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1627","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1628","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1629","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1630","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1631","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1632","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1633","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1634","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1635","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1636","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1637","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1638","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1639","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1640","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1641","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1642","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1643","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1644","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","FOS",""
"1645","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","1.5"
"1646","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","1.9"
"1647","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","FOS","2"
"1648","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1649","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1650","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1651","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1652","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1653","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1654","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1655","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1656","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1657","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1658","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1659","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1660","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1661","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1662","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1663","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1664","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1665","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1666","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1667","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1668","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1669","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","BCV",NA
"1670","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1671","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1672","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1673","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1674","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1675","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1676","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1677","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1678","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1679","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1680","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1681","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1682","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1683","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1684","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1685","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1686","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1687","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1688","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1689","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1690","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1691","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1692","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1693","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1694","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1695","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1696","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1697","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","BCV",NA
"1698","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1699","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1700","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","BCV",NA
"1701","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1702","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1703","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1704","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1705","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1706","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1707","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1708","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1709","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1710","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1711","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1712","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1713","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1714","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1715","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1716","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1717","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1718","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1719","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","BCV",NA
"1720","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","BCV",NA
"1721","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1722","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1723","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1724","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1725","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1726","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1727","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1728","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1729","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1730","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1731","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1732","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","BCV",NA
"1733","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","BCV",NA
"1734","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","BCV",NA
"1735","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","BCV",NA
"1736","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","BCV",NA
"1737","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1738","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1739","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1740","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","BCV",NA
"1741","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1742","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","BCV",NA
"1743","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","BCV",NA
"1744","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","BCV",NA
"1745","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1746","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1747","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1748","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","BCV",NA
"1749","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1750","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1751","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1752","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","BCV",NA
"1753","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1754","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1755","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1756","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1757","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1758","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1759","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1760","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1761","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1762","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1763","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1764","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1765","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1766","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1767","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1768","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1769","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1770","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1771","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1772","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1773","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1774","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1775","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1776","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1777","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1778","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1779","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1780","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1781","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1782","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1783","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1784","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1785","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1786","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","BCV",NA
"1787","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","BCV",NA
"1788","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","BCV",NA
"1789","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1790","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1791","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1792","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1793","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1794","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1795","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1796","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1797","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1798","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1799","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1800","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1801","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1802","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1803","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1804","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1805","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1806","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1807","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1808","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1809","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1810","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1811","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1812","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1813","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1814","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1815","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1816","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1817","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1818","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1819","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1820","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1821","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1822","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1823","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1824","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1825","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1826","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1827","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1828","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1829","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1830","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1831","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1832","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1833","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1834","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1835","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1836","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1837","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1838","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1839","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1840","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1841","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1842","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1843","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1844","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1845","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1846","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1847","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1848","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1849","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1850","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1851","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1852","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1853","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1854","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1855","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1856","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1857","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1858","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","BCV",NA
"1859","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1860","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1861","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1862","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1863","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","BCV",NA
"1864","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1865","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1866","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1867","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1868","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1869","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1870","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1871","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1872","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1873","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1874","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1875","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1876","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1877","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1878","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1879","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1880","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1881","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1882","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1883","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1884","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1885","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1886","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1887","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1888","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1889","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1890","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1891","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1892","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1893","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1894","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1895","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1896","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1897","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1898","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1899","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","BCV",NA
"1900","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","BCV",NA
"1901","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","BCV",NA
"1902","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","BCV",NA
"1903","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","BCV",NA
"1904","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","BCV",NA
"1905","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1906","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1907","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1908","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1909","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1910","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1911","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1912","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1913","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1914","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","BCV",NA
"1915","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","BCV",NA
"1916","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","BCV",NA
"1917","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","BCV",NA
"1918","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","BCV",NA
"1919","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1920","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1921","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1922","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1923","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1924","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1925","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1926","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1927","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1928","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1929","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1930","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1931","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1932","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1933","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1934","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","BCV",NA
"1935","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","BCV",NA
"1936","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1937","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1938","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1939","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1940","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1941","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1942","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1943","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1944","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1945","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1946","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1947","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","BCV",NA
"1948","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","BCV",NA
"1949","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","BCV",NA
"1950","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","BCV",NA
"1951","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","BCV",NA
"1952","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","BCV",NA
"1953","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","BCV",NA
"1954","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","BCV",NA
"1955","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1956","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1957","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"1958","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1959","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1960","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1961","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","BCV",NA
"1962","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1963","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1964","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1965","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1966","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1967","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1968","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1969","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1970","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1971","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1972","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1973","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1974","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1975","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1976","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1977","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1978","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1979","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1980","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1981","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1982","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1983","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1984","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1985","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1986","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1987","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1988","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"1989","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","BCV",NA
"1990","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","BCV",NA
"1991","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1992","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1993","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1994","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"1995","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","BCV",NA
"1996","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"1997","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"1998","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"1999","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2000","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2001","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2002","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2003","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2004","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2005","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2006","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2007","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2008","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2009","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2010","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2011","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2012","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2013","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2014","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2015","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2016","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2017","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2018","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2019","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2020","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2021","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2022","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2023","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2024","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2025","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2026","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2027","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2028","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2029","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2030","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2031","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2032","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2033","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2034","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2035","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2036","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2037","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2038","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2039","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2040","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2041","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2042","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2043","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2044","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2045","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2046","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2047","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2048","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2049","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2050","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2051","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","BCV",NA
"2052","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"2053","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","BCV",NA
"2054","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2055","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2056","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2057","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2058","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2059","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2060","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2061","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2062","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2063","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2064","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2065","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2066","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","BCV",NA
"2067","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2068","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2069","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2070","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2071","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2072","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2073","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2074","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2075","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2076","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2077","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2078","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2079","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2080","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","BCV",NA
"2081","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","BCV",NA
"2082","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","BCV",NA
"2083","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2084","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2085","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2086","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","BCV",NA
"2087","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2088","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2089","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2090","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","BCV",NA
"2091","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","BCV",NA
"2092","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","BCV",NA
"2093","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","BCV",NA
"2094","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","BCV",NA
"2095","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","BCV",NA
"2096","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2097","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2098","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2099","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2100","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2101","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2102","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2103","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2104","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2105","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2106","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2107","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2108","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2109","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2110","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2111","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2112","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2113","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2114","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2115","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2116","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2117","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2118","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2119","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2120","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2121","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2122","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2123","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2124","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2125","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2126","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2127","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2128","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2129","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2130","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2131","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2132","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","BCV",NA
"2133","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2134","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2135","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2136","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2137","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2138","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2139","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2140","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2141","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2142","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2143","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2144","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2145","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2146","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2147","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2148","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2149","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2150","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2151","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2152","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2153","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2154","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2155","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2156","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2157","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2158","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2159","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2160","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2161","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2162","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2163","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2164","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2165","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2166","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2167","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2168","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2169","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2170","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2171","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2172","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2173","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2174","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2175","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2176","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2177","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2178","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2179","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2180","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2181","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2182","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2183","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2184","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2185","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2186","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2187","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2188","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2189","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2190","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2191","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2192","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2193","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","BCV",NA
"2194","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"2195","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"2196","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","BCV",NA
"2197","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2198","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2199","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2200","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2201","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2202","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2203","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2204","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2205","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2206","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2207","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2208","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2209","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2210","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2211","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2212","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2213","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2214","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2215","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2216","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2217","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2218","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","Letermovir",""
"2219","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2220","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2221","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2222","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2223","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2224","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2225","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2226","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2227","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2228","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2229","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2230","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2231","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2232","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2233","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2234","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2235","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2236","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2237","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2238","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2239","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2240","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2241","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2242","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2243","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2244","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2245","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2246","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Letermovir",""
"2247","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2248","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2249","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Letermovir",""
"2250","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2251","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2252","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2253","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2254","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2255","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2256","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2257","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2258","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2259","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2260","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2261","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2262","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2263","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2264","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2265","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2266","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2267","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2268","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","Letermovir",""
"2269","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","Letermovir",""
"2270","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2271","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2272","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2273","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2274","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2275","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2276","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2277","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2278","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2279","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2280","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2281","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Letermovir",""
"2282","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Letermovir",""
"2283","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","Letermovir",""
"2284","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","Letermovir",""
"2285","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","Letermovir",""
"2286","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2287","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2288","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2289","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","Letermovir",""
"2290","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2291","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","Letermovir",""
"2292","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Letermovir",""
"2293","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Letermovir",""
"2294","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2295","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2296","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2297","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","Letermovir",""
"2298","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2299","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2300","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2301","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","Letermovir",""
"2302","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2303","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2304","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2305","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2306","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2307","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2308","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2309","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2310","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2311","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2312","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2313","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2314","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2315","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2316","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2317","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2318","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2319","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2320","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2321","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2322","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2323","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2324","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2325","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2326","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2327","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2328","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2329","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2330","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2331","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2332","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2333","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2334","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2335","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Letermovir",""
"2336","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","Letermovir",""
"2337","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","Letermovir",""
"2338","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2339","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2340","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2341","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2342","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2343","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2344","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2345","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2346","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2347","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2348","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2349","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2350","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2351","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2352","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2353","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2354","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2355","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2356","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2357","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2358","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2359","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2360","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2361","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2362","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2363","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2364","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2365","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2366","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2367","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2368","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2369","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2370","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2371","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2372","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2373","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2374","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2375","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2376","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2377","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2378","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2379","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2380","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2381","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2382","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2383","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2384","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2385","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.8"
"2386","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","0.6"
"2387","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","0.7"
"2388","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1"
"2389","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.5"
"2390","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","2.5"
"2391","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","17"
"2392","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","14"
"2393","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.5"
"2394","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","4.8"
"2395","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","4.5"
"2396","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","8"
"2397","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","16"
"2398","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","34"
"2399","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.8"
"2400","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.5"
"2401","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.1"
"2402","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2"
"2403","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.8"
"2404","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.2"
"2405","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.1"
"2406","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1"
"2407","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","Letermovir","1.2"
"2408","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","0.8"
"2409","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.3"
"2410","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","0.9"
"2411","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1"
"2412","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","Letermovir","1.2"
"2413","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.1"
"2414","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2415","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","5.4"
"2416","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir","0.8"
"2417","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.8"
"2418","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.1"
"2419","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","5.1"
"2420","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","17"
"2421","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.9"
"2422","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","14"
"2423","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","32"
"2424","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","10"
"2425","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","96"
"2426","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","3.3"
"2427","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","3.2"
"2428","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","8.6,14"
"2429","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","4.9"
"2430","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","14"
"2431","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","4.4"
"2432","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.8"
"2433","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","4.6"
"2434","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","3000"
"2435","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","3000"
"2436","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","3000"
"2437","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","9000"
"2438","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.9"
"2439","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","4.4"
"2440","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2"
"2441","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2"
"2442","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","5"
"2443","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","218"
"2444","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","45"
"2445","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","44"
"2446","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","13"
"2447","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","48"
"2448","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","Letermovir","46"
"2449","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","Letermovir","8.2"
"2450","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","Letermovir","104"
"2451","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","Letermovir","260"
"2452","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","Letermovir","3000"
"2453","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","Letermovir","54"
"2454","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.8"
"2455","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2"
"2456","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","1.7"
"2457","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.8"
"2458","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","34"
"2459","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","4.8"
"2460","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","8"
"2461","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","2.5"
"2462","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir","2.1"
"2463","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","Letermovir","6.3"
"2464","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","Letermovir","28"
"2465","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","Letermovir","126"
"2466","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","Letermovir","290"
"2467","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Letermovir","4"
"2468","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2469","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2470","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2471","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2472","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2473","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2474","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2475","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2476","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2477","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2478","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2479","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2480","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2481","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2482","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2483","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","Letermovir",""
"2484","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","Letermovir",""
"2485","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2486","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2487","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2488","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2489","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2490","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2491","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2492","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2493","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2494","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2495","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2496","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Letermovir",""
"2497","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","Letermovir",""
"2498","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Letermovir",""
"2499","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Letermovir",""
"2500","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Letermovir",""
"2501","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Letermovir",""
"2502","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Letermovir",""
"2503","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","Letermovir",""
"2504","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2505","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2506","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2507","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2508","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2509","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2510","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","Letermovir",""
"2511","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2512","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2513","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2514","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2515","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2516","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2517","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2518","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2519","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2520","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2521","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2522","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2523","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2524","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2525","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2526","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2527","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2528","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2529","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2530","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2531","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2532","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2533","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2534","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2535","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2536","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2537","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2538","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Letermovir",""
"2539","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Letermovir",""
"2540","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Letermovir","46"
"2541","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Letermovir","0.9"
"2542","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Letermovir","0.2"
"2543","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Letermovir","0.4"
"2544","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","Letermovir","R"
"2545","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2546","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2547","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2548","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2549","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2550","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2551","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2552","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2553","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2554","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2555","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2556","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2557","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2558","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2559","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2560","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2561","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2562","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2563","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2564","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2565","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2566","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2567","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2568","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2569","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2570","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2571","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2572","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2573","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2574","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2575","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2576","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2577","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2578","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2579","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2580","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2581","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2582","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2583","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2584","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2585","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2586","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2587","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2588","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2589","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2590","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2591","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2592","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2593","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2594","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2595","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2596","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2597","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2598","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2599","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir","R"
"2600","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2601","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2602","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Letermovir",""
"2603","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2604","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2605","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2606","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2607","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2608","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2609","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2610","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2611","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2612","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2613","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2614","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2615","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Letermovir",""
"2616","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2617","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2618","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2619","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2620","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2621","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2622","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2623","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2624","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2625","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2626","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2627","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2628","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2629","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Letermovir",""
"2630","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Letermovir",""
"2631","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","Letermovir",""
"2632","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2633","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2634","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2635","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","Letermovir",""
"2636","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2637","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2638","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2639","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Letermovir",""
"2640","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Letermovir",""
"2641","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Letermovir",""
"2642","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Letermovir",""
"2643","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Letermovir",""
"2644","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Letermovir",""
"2645","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2646","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2647","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2648","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2649","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2650","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2651","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2652","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2653","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2654","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2655","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2656","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2657","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2658","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2659","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2660","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2661","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2662","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2663","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2664","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2665","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2666","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2667","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2668","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2669","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2670","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2671","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2672","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2673","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2674","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2675","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2676","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2677","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2678","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2679","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2680","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2681","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Letermovir",""
"2682","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2683","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2684","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2685","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2686","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2687","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2688","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2689","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2690","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2691","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2692","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2693","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2694","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2695","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2696","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2697","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2698","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2699","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2700","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2701","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2702","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2703","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2704","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2705","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2706","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2707","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2708","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2709","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2710","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2711","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2712","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2713","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2714","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2715","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2716","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2717","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2718","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2719","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2720","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2721","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2722","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2723","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2724","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2725","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2726","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2727","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2728","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2729","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2730","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2731","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2732","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2733","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2734","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2735","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2736","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2737","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2738","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2739","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2740","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2741","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2742","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Letermovir",""
"2743","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2744","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2745","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Letermovir",""
"2746","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2747","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2748","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2749","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2750","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2751","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2752","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2753","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2754","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2755","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2756","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2757","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2758","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2759","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2760","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2761","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2762","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2763","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2764","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2765","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2766","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2767","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","Tomeglovir",NA
"2768","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2769","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2770","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2771","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2772","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2773","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2774","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2775","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2776","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2777","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2778","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2779","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2780","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2781","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2782","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2783","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2784","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2785","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2786","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2787","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2788","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2789","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2790","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2791","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2792","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2793","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2794","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2795","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Tomeglovir",NA
"2796","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2797","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2798","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Tomeglovir",NA
"2799","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2800","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2801","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2802","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2803","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2804","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2805","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2806","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2807","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2808","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2809","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2810","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2811","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2812","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2813","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2814","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2815","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2816","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2817","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","Tomeglovir",NA
"2818","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","Tomeglovir",NA
"2819","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2820","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2821","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2822","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2823","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2824","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2825","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2826","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2827","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2828","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2829","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2830","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Tomeglovir",NA
"2831","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Tomeglovir",NA
"2832","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","Tomeglovir",NA
"2833","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","Tomeglovir",NA
"2834","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","Tomeglovir",NA
"2835","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2836","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2837","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2838","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","Tomeglovir",NA
"2839","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2840","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","Tomeglovir",NA
"2841","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Tomeglovir",NA
"2842","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Tomeglovir",NA
"2843","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2844","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2845","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2846","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","Tomeglovir",NA
"2847","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2848","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2849","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2850","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","Tomeglovir",NA
"2851","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2852","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2853","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2854","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2855","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2856","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2857","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2858","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2859","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2860","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2861","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2862","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2863","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2864","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2865","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2866","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2867","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2868","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2869","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2870","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2871","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2872","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2873","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2874","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2875","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2876","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2877","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2878","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2879","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2880","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2881","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2882","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2883","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2884","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2885","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","Tomeglovir",NA
"2886","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2887","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2888","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2889","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2890","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2891","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2892","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2893","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2894","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2895","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2896","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2897","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2898","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2899","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2900","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2901","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2902","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2903","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2904","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2905","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2906","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2907","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2908","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2909","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2910","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2911","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2912","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2913","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2914","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2915","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2916","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2917","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2918","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2919","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2920","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2921","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2922","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2923","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2924","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2925","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2926","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2927","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2928","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2929","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2930","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2931","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2932","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2933","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2934","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","1.7"
"2935","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.3"
"2936","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.4"
"2937","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.8"
"2938","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","2.7"
"2939","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir","5.8"
"2940","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","2.7"
"2941","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.3"
"2942","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","1"
"2943","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir","2.1"
"2944","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","1.1"
"2945","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir","2.2"
"2946","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.3"
"2947","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir","0.6"
"2948","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","6.5"
"2949","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","7.4"
"2950","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.9"
"2951","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","15"
"2952","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","8.7"
"2953","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","98"
"2954","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","29"
"2955","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","15"
"2956","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","Tomeglovir","12"
"2957","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","3.4"
"2958","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","6"
"2959","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","2"
"2960","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","10"
"2961","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","Tomeglovir","17"
"2962","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir","0.4"
"2963","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2964","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2965","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"2966","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2967","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2968","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2969","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2970","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2971","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2972","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2973","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2974","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2975","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2976","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2977","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2978","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2979","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2980","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2981","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2982","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2983","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2984","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2985","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2986","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2987","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2988","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2989","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2990","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2991","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2992","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2993","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2994","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2995","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2996","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"2997","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","Tomeglovir",NA
"2998","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","Tomeglovir",NA
"2999","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","Tomeglovir",NA
"3000","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","Tomeglovir",NA
"3001","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","Tomeglovir",NA
"3002","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","Tomeglovir",NA
"3003","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3004","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3005","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3006","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3007","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir",NA
"3008","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir",NA
"3009","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir",NA
"3010","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir",NA
"3011","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3012","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","Tomeglovir",NA
"3013","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","Tomeglovir",NA
"3014","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","Tomeglovir",NA
"3015","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","Tomeglovir",NA
"3016","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Tomeglovir",NA
"3017","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3018","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3019","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3020","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3021","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3022","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3023","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3024","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3025","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3026","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3027","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3028","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3029","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3030","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3031","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3032","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","Tomeglovir",NA
"3033","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","Tomeglovir",NA
"3034","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3035","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3036","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3037","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3038","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3039","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3040","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3041","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3042","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3043","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3044","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3045","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Tomeglovir",NA
"3046","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","Tomeglovir",NA
"3047","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Tomeglovir",NA
"3048","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Tomeglovir",NA
"3049","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Tomeglovir",NA
"3050","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Tomeglovir",NA
"3051","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Tomeglovir",NA
"3052","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","Tomeglovir",NA
"3053","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3054","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3055","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3056","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3057","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3058","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3059","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","Tomeglovir",NA
"3060","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3061","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3062","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3063","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3064","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3065","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3066","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3067","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3068","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3069","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3070","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3071","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3072","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3073","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3074","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3075","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3076","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3077","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3078","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3079","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3080","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3081","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3082","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3083","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3084","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3085","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3086","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3087","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Tomeglovir",NA
"3088","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Tomeglovir",NA
"3089","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3090","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3091","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3092","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3093","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","Tomeglovir",NA
"3094","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3095","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3096","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3097","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3098","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3099","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3100","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3101","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3102","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3103","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3104","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3105","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3106","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3107","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3108","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3109","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3110","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3111","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3112","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3113","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3114","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3115","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3116","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3117","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3118","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3119","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3120","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3121","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3122","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3123","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3124","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3125","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3126","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3127","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3128","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3129","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3130","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3131","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3132","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3133","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3134","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3135","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3136","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3137","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3138","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3139","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3140","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3141","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3142","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3143","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3144","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3145","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3146","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3147","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3148","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3149","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3150","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3151","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3152","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3153","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3154","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3155","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3156","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3157","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3158","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3159","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3160","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3161","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3162","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3163","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3164","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Tomeglovir",NA
"3165","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3166","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3167","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3168","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3169","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3170","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3171","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3172","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3173","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3174","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3175","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3176","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3177","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3178","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3179","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3180","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3181","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3182","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3183","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3184","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","Tomeglovir",NA
"3185","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3186","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3187","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3188","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3189","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3190","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3191","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3192","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3193","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Tomeglovir",NA
"3194","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3195","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3196","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3197","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3198","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3199","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3200","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3201","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3202","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3203","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3204","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3205","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3206","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3207","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3208","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3209","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3210","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3211","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3212","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3213","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3214","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3215","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3216","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3217","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3218","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3219","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3220","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3221","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3222","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3223","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3224","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3225","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3226","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3227","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3228","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3229","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3230","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3231","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3232","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3233","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3234","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3235","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3236","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3237","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3238","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3239","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3240","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3241","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3242","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3243","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3244","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3245","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3246","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3247","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3248","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3249","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3250","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3251","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3252","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3253","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3254","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3255","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3256","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3257","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3258","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3259","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3260","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3261","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3262","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3263","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3264","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3265","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3266","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3267","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3268","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3269","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3270","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3271","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3272","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3273","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3274","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3275","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3276","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3277","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3278","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3279","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3280","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3281","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3282","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3283","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3284","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3285","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3286","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3287","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3288","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3289","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3290","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3291","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3292","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3293","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3294","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Tomeglovir",NA
"3295","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3296","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3297","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3298","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3299","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3300","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3301","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3302","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3303","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3304","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3305","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3306","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3307","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3308","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3309","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3310","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3311","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3312","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3313","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3314","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3315","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3316","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","GW275175",NA
"3317","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3318","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3319","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3320","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3321","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3322","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3323","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3324","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3325","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3326","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3327","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3328","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3329","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3330","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3331","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3332","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3333","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3334","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3335","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3336","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3337","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3338","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3339","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3340","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3341","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3342","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3343","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3344","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","GW275175",NA
"3345","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3346","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3347","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","GW275175",NA
"3348","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3349","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3350","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3351","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3352","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3353","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3354","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3355","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3356","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3357","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3358","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3359","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3360","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3361","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3362","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3363","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3364","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3365","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3366","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","GW275175",NA
"3367","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","GW275175",NA
"3368","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3369","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3370","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3371","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3372","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3373","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3374","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3375","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3376","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3377","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3378","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3379","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","GW275175",NA
"3380","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","GW275175",NA
"3381","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","GW275175",NA
"3382","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","GW275175",NA
"3383","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","GW275175",NA
"3384","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3385","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3386","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3387","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","GW275175",NA
"3388","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3389","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","GW275175",NA
"3390","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","GW275175",NA
"3391","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","GW275175",NA
"3392","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3393","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3394","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3395","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","GW275175",NA
"3396","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3397","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3398","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3399","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","GW275175",NA
"3400","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3401","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3402","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3403","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3404","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3405","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3406","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3407","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3408","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3409","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3410","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3411","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3412","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3413","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3414","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3415","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3416","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3417","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3418","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3419","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3420","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3421","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3422","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3423","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3424","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3425","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3426","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3427","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3428","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3429","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3430","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3431","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3432","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3433","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","GW275175",NA
"3434","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","GW275175",NA
"3435","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","GW275175",NA
"3436","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3437","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3438","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3439","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3440","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3441","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3442","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3443","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3444","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3445","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3446","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3447","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3448","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3449","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3450","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3451","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3452","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3453","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3454","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3455","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3456","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3457","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3458","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3459","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3460","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3461","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3462","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3463","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3464","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3465","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3466","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3467","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3468","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3469","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3470","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3471","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3472","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3473","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3474","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3475","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3476","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3477","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3478","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3479","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3480","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3481","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3482","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3483","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","9.4"
"3484","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","27"
"3485","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","8.5"
"3486","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3487","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","4.2"
"3488","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175","21"
"3489","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.8"
"3490","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3491","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3492","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175","10"
"3493","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.8"
"3494","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175","10"
"3495","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.5"
"3496","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175","7.4"
"3497","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","4.2"
"3498","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.5"
"3499","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.9"
"3500","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3501","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","5.1"
"3502","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.6"
"3503","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.9"
"3504","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3505","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","GW275175","0.6"
"3506","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.7"
"3507","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.9"
"3508","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.9"
"3509","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","0.9"
"3510","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","GW275175","0.8"
"3511","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175","1"
"3512","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3513","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3514","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3515","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3516","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3517","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3518","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3519","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3520","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3521","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3522","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3523","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3524","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3525","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3526","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3527","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3528","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3529","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3530","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3531","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3532","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3533","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3534","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3535","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3536","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3537","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3538","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3539","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3540","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3541","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3542","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3543","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3544","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3545","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3546","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","GW275175",NA
"3547","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","GW275175",NA
"3548","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","GW275175",NA
"3549","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","GW275175",NA
"3550","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","GW275175",NA
"3551","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","GW275175",NA
"3552","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3553","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3554","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3555","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3556","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175",NA
"3557","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175",NA
"3558","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175",NA
"3559","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175",NA
"3560","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3561","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","GW275175",NA
"3562","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","GW275175",NA
"3563","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","GW275175",NA
"3564","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","GW275175",NA
"3565","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","GW275175",NA
"3566","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3567","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3568","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3569","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3570","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3571","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3572","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3573","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3574","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3575","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3576","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3577","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3578","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3579","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3580","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3581","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","GW275175",NA
"3582","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","GW275175",NA
"3583","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3584","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3585","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3586","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3587","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3588","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3589","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3590","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3591","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3592","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3593","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3594","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","GW275175",NA
"3595","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","GW275175",NA
"3596","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","GW275175",NA
"3597","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","GW275175",NA
"3598","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GW275175",NA
"3599","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GW275175",NA
"3600","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","GW275175",NA
"3601","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","GW275175",NA
"3602","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3603","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3604","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3605","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3606","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3607","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3608","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","GW275175",NA
"3609","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3610","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3611","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3612","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3613","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3614","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3615","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3616","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3617","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3618","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3619","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3620","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3621","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3622","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3623","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3624","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3625","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3626","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3627","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3628","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3629","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3630","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3631","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3632","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3633","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3634","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3635","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3636","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","GW275175",NA
"3637","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","GW275175",NA
"3638","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3639","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3640","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3641","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3642","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","GW275175",NA
"3643","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3644","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3645","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3646","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3647","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3648","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3649","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3650","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3651","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3652","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3653","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3654","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3655","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3656","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3657","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3658","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3659","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3660","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3661","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3662","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3663","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3664","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3665","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3666","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3667","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3668","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3669","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3670","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3671","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3672","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3673","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3674","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3675","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3676","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3677","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3678","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3679","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3680","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3681","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3682","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3683","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3684","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3685","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3686","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3687","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3688","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3689","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3690","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3691","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3692","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3693","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3694","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3695","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3696","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3697","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3698","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3699","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3700","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","GW275175",NA
"3701","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3702","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3703","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3704","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3705","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3706","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3707","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3708","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3709","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3710","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3711","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3712","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3713","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","GW275175",NA
"3714","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3715","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3716","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3717","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3718","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3719","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3720","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3721","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3722","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3723","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3724","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3725","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3726","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3727","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","GW275175",NA
"3728","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","GW275175",NA
"3729","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","GW275175",NA
"3730","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3731","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3732","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3733","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","GW275175",NA
"3734","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3735","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3736","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3737","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","GW275175",NA
"3738","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GW275175",NA
"3739","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GW275175",NA
"3740","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GW275175",NA
"3741","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","GW275175",NA
"3742","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","GW275175",NA
"3743","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3744","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3745","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3746","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3747","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3748","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3749","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3750","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3751","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3752","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3753","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3754","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3755","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3756","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3757","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3758","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3759","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3760","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3761","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3762","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3763","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3764","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3765","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3766","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3767","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3768","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3769","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3770","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3771","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3772","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3773","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3774","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3775","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3776","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3777","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3778","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3779","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","GW275175",NA
"3780","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3781","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3782","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3783","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3784","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3785","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3786","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3787","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3788","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3789","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3790","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3791","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3792","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3793","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3794","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3795","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3796","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3797","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3798","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3799","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3800","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3801","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3802","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3803","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3804","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3805","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3806","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3807","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3808","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3809","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3810","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3811","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3812","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3813","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3814","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3815","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3816","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3817","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3818","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3819","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3820","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3821","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3822","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3823","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3824","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3825","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3826","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3827","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3828","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3829","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3830","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3831","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3832","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3833","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3834","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3835","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3836","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3837","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3838","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3839","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3840","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","GW275175",NA
"3841","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3842","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3843","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","GW275175",NA
"3844","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3845","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"3846","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3847","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3848","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3849","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3850","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3851","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3852","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3853","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3854","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3855","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3856","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3857","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3858","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3859","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3860","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3861","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3862","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3863","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3864","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3865","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","Maribavir",""
"3866","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3867","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3868","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"3869","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3870","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3871","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3872","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"3873","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3874","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"3875","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3876","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3877","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3878","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3879","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3880","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3881","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"3882","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3883","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3884","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3885","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3886","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3887","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3888","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"3889","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3890","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3891","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"3892","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3893","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Maribavir",""
"3894","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3895","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3896","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Maribavir",""
"3897","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3898","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3899","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3900","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3901","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3902","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3903","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3904","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3905","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3906","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3907","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3908","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3909","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3910","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3911","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3912","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3913","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3914","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3915","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","Maribavir",""
"3916","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","Maribavir",""
"3917","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3918","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3919","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3920","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3921","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3922","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3923","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3924","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"3925","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3926","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3927","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3928","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Maribavir",""
"3929","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Maribavir",""
"3930","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","Maribavir",""
"3931","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","Maribavir",""
"3932","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","Maribavir",""
"3933","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3934","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3935","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3936","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","Maribavir",""
"3937","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3938","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","Maribavir",""
"3939","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Maribavir",""
"3940","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Maribavir",""
"3941","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3942","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3943","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3944","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","Maribavir",""
"3945","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3946","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3947","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3948","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","Maribavir",""
"3949","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3950","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"3951","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"3952","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3953","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3954","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3955","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3956","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3957","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3958","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3959","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3960","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3961","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3962","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3963","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3964","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3965","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3966","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3967","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3968","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3969","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3970","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3971","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3972","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3973","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3974","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3975","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3976","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3977","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3978","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3979","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3980","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3981","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3982","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Maribavir",""
"3983","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","Maribavir",""
"3984","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","Maribavir",""
"3985","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3986","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3987","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3988","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3989","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3990","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3991","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3992","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3993","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3994","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3995","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3996","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3997","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3998","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"3999","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4000","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4001","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4002","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4003","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4004","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4005","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4006","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4007","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4008","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4009","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4010","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4011","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4012","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4013","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4014","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4015","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4016","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4017","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4018","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4019","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4020","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4021","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4022","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4023","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4024","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4025","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4026","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4027","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4028","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4029","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4030","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4031","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4032","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4033","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4034","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4035","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4036","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4037","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4038","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4039","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4040","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4041","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4042","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4043","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4044","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4045","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4046","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4047","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4048","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4049","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4050","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4051","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4052","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4053","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4054","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","Maribavir",""
"4055","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4056","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4057","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4058","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4059","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","Maribavir",""
"4060","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4061","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4062","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4063","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4064","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4065","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4066","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4067","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4068","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4069","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4070","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4071","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4072","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4073","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4074","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4075","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4076","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4077","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4078","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4079","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4080","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4081","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4082","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4083","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4084","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4085","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4086","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4087","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4088","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4089","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4090","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4091","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4092","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4093","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4094","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4095","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","Maribavir",""
"4096","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","Maribavir",""
"4097","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","Maribavir",""
"4098","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","Maribavir",""
"4099","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","Maribavir",""
"4100","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","Maribavir",""
"4101","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4102","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4103","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4104","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4105","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4106","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4107","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4108","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4109","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",""
"4110","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","Maribavir",""
"4111","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","Maribavir",""
"4112","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","Maribavir",""
"4113","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","Maribavir",""
"4114","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Maribavir",""
"4115","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","3.4"
"4116","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","18"
"4117","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","10"
"4118","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","304"
"4119","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","108"
"4120","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir",">200"
"4121","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","81"
"4122","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","69"
"4123","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","9"
"4124","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","12"
"4125","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","278"
"4126","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","321"
"4127","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","243"
"4128","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","445"
"4129","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","372"
"4130","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","Maribavir","227"
"4131","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","Maribavir","164"
"4132","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2"
"4133","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","1.7"
"4134","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2.6"
"4135","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2.5"
"4136","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","1.8,4.8"
"4137","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2"
"4138","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","3.1"
"4139","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","23"
"4140","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2.1"
"4141","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","1.9"
"4142","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2.2"
"4143","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Maribavir","2.2"
"4144","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","Maribavir","3.5"
"4145","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Maribavir","7.2"
"4146","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Maribavir","27"
"4147","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Maribavir","R"
"4148","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Maribavir","R"
"4149","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Maribavir","R"
"4150","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","Maribavir",""
"4151","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir","4.5"
"4152","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4153","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir","18"
"4154","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir","90"
"4155","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir","1.2"
"4156","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir","1.3"
"4157","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","Maribavir","56"
"4158","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4159","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4160","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4161","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4162","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4163","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4164","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4165","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4166","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4167","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4168","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4169","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4170","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4171","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4172","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4173","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4174","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4175","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4176","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4177","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4178","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4179","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4180","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4181","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4182","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4183","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4184","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4185","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Maribavir",""
"4186","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Maribavir",""
"4187","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4188","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4189","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4190","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4191","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","Maribavir",""
"4192","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4193","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4194","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4195","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4196","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4197","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4198","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4199","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4200","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4201","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4202","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4203","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4204","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4205","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4206","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4207","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4208","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4209","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4210","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4211","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4212","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4213","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4214","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4215","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4216","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4217","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4218","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4219","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4220","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4221","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4222","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4223","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4224","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4225","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4226","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4227","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4228","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4229","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4230","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4231","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4232","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4233","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4234","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4235","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4236","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4237","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4238","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4239","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4240","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4241","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4242","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4243","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4244","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4245","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4246","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4247","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4248","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4249","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Maribavir",""
"4250","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4251","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4252","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4253","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4254","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4255","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4256","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4257","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4258","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4259","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4260","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4261","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4262","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Maribavir",""
"4263","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4264","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4265","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4266","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4267","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4268","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4269","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4270","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4271","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4272","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4273","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4274","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4275","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4276","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Maribavir",""
"4277","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Maribavir",""
"4278","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","Maribavir",""
"4279","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4280","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4281","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4282","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","Maribavir",""
"4283","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4284","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4285","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4286","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Maribavir",""
"4287","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Maribavir",""
"4288","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Maribavir",""
"4289","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Maribavir",""
"4290","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Maribavir",""
"4291","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Maribavir",""
"4292","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4293","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4294","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4295","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4296","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4297","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4298","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4299","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4300","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4301","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4302","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4303","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4304","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4305","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4306","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4307","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4308","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4309","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4310","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4311","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4312","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4313","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4314","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4315","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4316","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4317","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4318","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4319","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4320","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4321","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4322","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4323","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4324","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4325","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4326","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4327","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4328","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Maribavir",""
"4329","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4330","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4331","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4332","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4333","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4334","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4335","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4336","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4337","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4338","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4339","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4340","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4341","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4342","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4343","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4344","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4345","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4346","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4347","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4348","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4349","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4350","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4351","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4352","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4353","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4354","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4355","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4356","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4357","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4358","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4359","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4360","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4361","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4362","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4363","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4364","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4365","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4366","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4367","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4368","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4369","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4370","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4371","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4372","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4373","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4374","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4375","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4376","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4377","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4378","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4379","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4380","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4381","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4382","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4383","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4384","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4385","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4386","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4387","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4388","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4389","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Maribavir",""
"4390","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4391","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4392","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Maribavir",""
"4393","65","HCMV","TOWNE","UL54","D301N","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4394","","","AD169","UL54","C304S","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4395","66","HCMV","TOWNE","UL54","N408D","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4396","67","AD169","AD169","UL54","N408K","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4397","68","HCMV","AD169","UL54","N408S","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4398","69","HCMV","TOWNE","UL54","N410K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4399","70","HCMV","TOWNE","UL54","F412C","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4400","71","HCMV","AD169","UL54","F412L","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4401","72","HCMV","AD169","UL54","F412S","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4402","73","HCMV","TOWNE","UL54","F412V","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4403","74","HCMV","MERLIN","UL54","D413A","Rev. Med. Virol. 2016; 26: 161–182","[51,82]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4404","75","HCMV","TOWNE","UL54","D413E","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4405","76","HCMV","AD169","UL54","D413N","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4406","77","HCMV","Susceptable Clinical Isolate","UL54","P488R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4407","78","HCMV","MERLIN","UL54","N495K","Rev. Med. Virol. 2016; 26: 161–182","A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","Antiviral Therapy 2006;","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4408","79","HCMV","AD169","UL54","K500N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","11: 537–540.","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4409","80","HCMV","TOWNE","UL54","L501I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4410","81","HCMV","TOWNE","UL54","T503I","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4411","review reference wrong","HCMV","MERLIN","UL54","A505V","Rev. Med. Virol. 2016; 26: 161–182","125","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4412","83","HCMV","TOWNE","UL54","K513E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4413","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4414","84","HCMV","MERLIN","UL54","K513N","Rev. Med. Virol. 2016; 26: 161–182","A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture","https://www.sciencedirect.com/science/article/pii/S0042682298992996","https://doi.org/10.1006/viro.1998.9299","Marker Transfer, Plaque Reduction Assay","in vitro","strong","Tested","UL54","V812L","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4415","85","HCMV","AD169","UL54","K513R","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4416","86","HCMV","MERLIN","UL54","D515E","Rev. Med. Virol. 2016; 26: 161–182","[70]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4417","","HCMV","TOWNE","UL54","D515G","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4418","87","HCMV","MERLIN","UL54","D515Y","Rev. Med. Virol. 2016; 26: 161–182","[79]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4419","88","HCMV","TOWNE","UL54","L516R","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4420","89","HCMV","MERLIN","UL54","I521T","Rev. Med. Virol. 2016; 26: 161–182","[51,70,127]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4421","","","AD169","UL54","I521T","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4422","90","HCMV","AD169","UL54","P522A","Rev. Med. Virol. 2016; 26: 161–182","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4423","","","AD169","UL54","P522L","","Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf","doi:10.1016/j.jcv.2008.04.005.","Marker Transfer , SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4424","91","HCMV","TOWNE","UL54","P522S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4425","92","HCMV","AD169","UL54","524del","Rev. Med. Virol. 2016; 26: 161–182","Novel DNA polymerase mutations conferring cytomegalovirus
resistance: Input of BAC-recombinant phenotyping and 3D model","https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259?via%3Dihub","https://doi.org/10.1016/j.antiviral.2013.02.002","BAC recombinant, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4426","93","HCMV","MERLIN","UL54","V526L","Rev. Med. Virol. 2016; 26: 161–182","[98]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4427","94","HCMV","AD169","UL54","C539G","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4428","95","HCMV","Susceptable Clinical Isolate","UL54","C539R","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4429","96","HCMV","MERLIN","UL54","D542E","Rev. Med. Virol. 2016; 26: 161–182","[129]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4430","","","AD169","UL54","V544A","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4431","97","HCMV","TOWNE","UL54","L545S","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4432","98","HCMV","AD169","UL54","L545W","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4433","99","HCMV","AD169","UL54","T552N","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4434","100","HCMV","AD169","UL54","Q578H","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4435","102","HCMV","AD169","UL54","S585A","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4436","103","HCMV","TOWNE","UL54","D588E","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4437","","","AD169","UL54","D588N","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4438","104","HCMV","MERLIN","UL54","D588N","Rev. Med. Virol. 2016; 26: 161–182","[51,67,72,83,122]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4439","105","HCMV","Susceptable Clinical Isolate","UL54","F595I","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4440","","HCMV","TOWNE","UL54","A692S","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4441","106","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4442","folloup values in review paper","HCMV","MERLIN","UL54","T700A","Rev. Med. Virol. 2016; 26: 161–182","[51,54,69,78,118]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Cyclopropavir",NA
"4443","","HCMV","AD169","UL54","A714V","","Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/","doi: 10.1016/j.jcv.2011.01.004","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4444","107","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4445","folloup values in review paper","HCMV","MERLIN","UL54","V715M","Rev. Med. Virol. 2016; 26: 161–182"," ","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","U","Cyclopropavir",NA
"4446","109","HCMV","AD169","UL54","I726V","Rev. Med. Virol. 2016; 26: 161–182","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4447","110","HCMV","TOWNE","UL54","E756D","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4448","review wrong ref & value","HCMV","TOWNE","UL54","E756K","Rev. Med. Virol. 2016; 26: 161–182","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4449","112","HCMV","MERLIN","UL54","E756Q","Rev. Med. Virol. 2016; 26: 161–182","[128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4450","113","HCMV","AD169","UL54","L773V","Rev. Med. Virol. 2016; 26: 161–182","Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/","doi: 10.1128/AAC.03214-14","BAC recombinant, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4451","114","HCMV","MERLIN","UL54","L776M","Rev. Med. Virol. 2016; 26: 161–182","[51,133]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4452","115","HCMV","TOWNE","UL54","V781I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4453","116","HCMV","MERLIN","UL54","V787A","Rev. Med. Virol. 2016; 26: 161–182","[92]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4454","117","HCMV","MERLIN","UL54","V787L","Rev. Med. Virol. 2016; 26: 161–182","[80,119,128]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4455","118","HCMV","TOWNE","UL54","L802M","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4456","119","HCMV","AD169","UL54","L802V","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4457","120","HCMV","TOWNE","UL54","K805Q","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4458","121","HCMV","MERLIN","UL54","A809V","Rev. Med. Virol. 2016; 26: 161–182","[65,90,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4459","","","AD169","UL54","A809V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4460","122","HCMV","MERLIN","UL54","V812L","Rev. Med. Virol. 2016; 26: 161–182","[83,119,126]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4461","123","HCMV","MERLIN","UL54","T813S","Rev. Med. Virol. 2016; 26: 161–182","[90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4462","124","HCMV","TOWNE","UL54","T821I","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4463","125","HCMV","MERLIN","UL54","P829S","Rev. Med. Virol. 2016; 26: 161–182","[49,119]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4464","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","","","","OJCharles","","","Cyclopropavir",NA
"4465","126","HCMV","AD169","UL54","A834P","Rev. Med. Virol. 2016; 26: 161–182","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, SEAP assay","in vitro","strong","Tested","UL54","N408K","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4466","127","HCMV","MERLIN","UL54","T838A","Rev. Med. Virol. 2016; 26: 161–182","[83]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4467","128","HCMV","MERLIN","UL54","G841A","Rev. Med. Virol. 2016; 26: 161–182","[72,78,90]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4468","130","HCMV","MERLIN","UL54","M844T","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4469","131","HCMV","MERLIN","UL54","M844V","Rev. Med. Virol. 2016; 26: 161–182","[135]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4470","132","HCMV","Susceptable Clinical Isolate","UL54","L862F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4471","133","HCMV","Susceptable Clinical Isolate","UL54","V946L","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4472","134","HCMV","AD169","UL54","L957F","Rev. Med. Virol. 2016; 26: 161–182","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4473","","HCMV","TOWNE","UL54","G971D","","Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus","https://academic.oup.com/jid/article/188/1/32/821141","https://doi.org/10.1086/375743","Marker transfer, plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4474","135","HCMV","MERLIN","UL54","del981-2","Rev. Med. Virol. 2016; 26: 161–182","[76,97,117,123]","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4475","","","AD169","UL54","A987G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4476","136","HCMV","TOWNE","UL54","A987G","Rev. Med. Virol. 2016; 26: 161–182","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4477","","HCMV","TOWNE","UL54","S676G","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Cyclopropavir",NA
"4478","","HCMV","TOWNE","UL54","V759M","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","","","16/03/2020","OJCharles","","","Cyclopropavir",NA
"4479","","HCMV","TOWNE","UL54","F412C","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","L802M","16/03/2020","OJCharles","","","Cyclopropavir",NA
"4480","","HCMV","TOWNE","UL54","K513E","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","D558E","","","","","Cyclopropavir",NA
"4481","","HCMV","TOWNE","UL54","K805Q","","Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/","","Cotransfection of overlapp, plaque reduction assay","in vitro","strong","Tested","UL54","T821I","","","","","Cyclopropavir",NA
"4482","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4483","","HCMV","AD169","UL54","V812L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4484","","HCMV","AD169","UL54","879G","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4485","","HCMV","AD169","UL54","L545S","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","P829S","","","","","Cyclopropavir",NA
"4486","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4487","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","T552N","","","","","Cyclopropavir",NA
"4488","","HCMV","AD169","UL54","N408D","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Cyclopropavir",NA
"4489","","HCMV","AD169","UL54","T552N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","L957F","","","","","Cyclopropavir",NA
"4490","","HCMV","AD169","UL54","757K","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4491","","HCMV","AD169","UL54","L802M","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4492","","HCMV","AD169","UL54","926V","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4493","","HCMV","AD169","UL54","K500N","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","UL54","S585A","","","","","Cyclopropavir",NA
"4494","","HCMV","Susceptable Clinical Isolate","UL54","V787L","","Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/","","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4495","","HCMV","AD169","UL97","del590-593","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4496","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4497","","HCMV","AD169","UL54","L545S","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","UL97","M460I","","","","","Cyclopropavir",NA
"4498","","HCMV","AD169","UL54","T552N","","New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/","","Lab-drived mutant, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4499","","HCMV","TOWNE","UL54","L737M","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4500","","HCMV","TOWNE","UL54","A834P","","Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.","https://europepmc.org/article/pmc/pmc1797699","DOI: 10.1128/AAC.00633-06","Marker transfer, Plaque Reduction Assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4501","","","AD169","UL54","Q229K","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4502","","","AD169","UL54","D247N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4503","","","AD169","UL54","D262N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4504","","","AD169","UL54","T271A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4505","","","AD169","UL54","V284E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4506","","","AD169","UL54","D288N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4507","","","AD169","UL54","F396L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4508","","","AD169","UL54","L424V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4509","","","AD169","UL54","T437M","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4510","","","AD169","UL54","F460L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4511","","","AD169","UL54","A505V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4512","","","AD169","UL54","A543S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4513","","","AD169","UL54","S612N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4514","","","AD169","UL54","V654G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4515","","","AD169","UL54","S660G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4516","","","AD169","UL54","S660N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4517","","","AD169","UL54","G667N","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4518","","","AD169","UL54","A692G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4519","","","AD169","UL54","I726T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4520","","","AD169","UL54","E793V","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4521","","","AD169","UL54","Q795P","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4522","","","AD169","UL54","Q795R","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4523","","","AD169","UL54","G841S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4524","","","AD169","UL54","P859A","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4525","","","AD169","UL54","V902G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4526","","","AD169","UL54","E903G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4527","","","AD169","UL54","K947E","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4528","","","AD169","UL54","M959T","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4529","","","AD169","UL54","N345S","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4530","","","AD169","UL54","V467G","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4531","","","AD169","UL54","Q578L","","Phenotypic
evaluation of previously
uncharacterized cytomegalovirus DNA
polymerase sequence variants detected in
a valganciclovir treatment trial","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/","doi: 10.1093/infdis/jit654","Recombinant BAC, PRA","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4532","relook","","MERLIN","UL97","L595T","Rev. Med. Virol. 2016; 26: 161–182","","","",NA,NA,NA,"Tested","","","17/11/2019","OJCharles","review has no reference or data for mention","","Cyclopropavir",NA
"4533","relook","HCMV","MERLIN","UL97","D605E","Rev. Med. Virol. 2016; 26: 161–182","","","","Clinical Isolate","Potential","weak","Hypothesised","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4534","18","HCMV","MERLIN","UL97","F342S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4535","19","HCMV","MERLIN","UL97","del355","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4536","20","HCMV","MERLIN","UL97","V356G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4537","21","HCMV","MERLIN","UL97","L405P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4538","22","HCMV","MERLIN","UL97","D456N","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4539","23","HCMV","MERLIN","UL97","M460I","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4540","24","HCMV","MERLIN","UL97","M460T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4541","25","HCMV","MERLIN","UL97","M460V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4542","26","HCMV","MERLIN","UL97","V466G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4543","27","HCMV","MERLIN","UL97","C480R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4544","28","HCMV","MERLIN","UL97","C518Y","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4545","29","HCMV","MERLIN","UL97","H520Q","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4546","30","HCMV","MERLIN","UL97","P521L","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4547","31","HCMV","MERLIN","UL97","del591-594","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4548","32","HCMV","MERLIN","UL97","del590-600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4549","33","HCMV","MERLIN","UL97","del590-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4550","34","HCMV","MERLIN","UL97","A591V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4551","35","HCMV","MERLIN","UL97","del591-607","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4552","36","HCMV","MERLIN","UL97","C592F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4553","37","HCMV","MERLIN","UL97","C592G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4554","38","HCMV","MERLIN","UL97","A594E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4555","39","HCMV","MERLIN","UL97","A594G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4556","40","HCMV","MERLIN","UL97","A594P","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4557","41","HCMV","MERLIN","UL97","A594T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4558","42","HCMV","MERLIN","UL97","A594V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4559","43","HCMV","MERLIN","UL97","L595F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4560","44","HCMV","MERLIN","UL97","L595S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4561","45","HCMV","MERLIN","UL97","L595W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4562","46","HCMV","MERLIN","UL97","del595","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4563","47","HCMV","MERLIN","UL97","del595-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4564","48","HCMV","MERLIN","UL97","del596","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4565","49","HCMV","MERLIN","UL97","E596G","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4566","50","HCMV","MERLIN","UL97","E596Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4567","51","HCMV","MERLIN","UL97","G598S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4568","52","HCMV","MERLIN","UL97","K599E","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4569","53","HCMV","MERLIN","UL97","K599T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4570","54","HCMV","MERLIN","UL97","del600","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4571","55","HCMV","MERLIN","UL97","del601-603","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4572","56","HCMV","MERLIN","UL97","C603R","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4573","57","HCMV","MERLIN","UL97","C603S","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4574","58","HCMV","MERLIN","UL97","C603W","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4575","59","HCMV","MERLIN","UL97","C607F","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4576","60","HCMV","MERLIN","UL97","C607Y*","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4577","61","HCMV","MERLIN","UL97","I610T","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4578","62","HCMV","MERLIN","UL97","A613V","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4579","63","HCMV","MERLIN","UL97","del617","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4580","64","HCMV","MERLIN","UL97","E655K","Rev. Med. Virol. 2016; 26: 161–182","","","","","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4581","137","HCMV","AD169","UL89","D344E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-17","https://doi.org/10
.1128/AAC.01325-17","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4582","138","HCMV","AD169","UL89","C347S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-18","https://doi.org/10
.1128/AAC.01325-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4583","139","HCMV","AD169","UL89","R351H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-19","https://doi.org/10
.1128/AAC.01325-19","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4584","140","HCMV","AD169","UL56","E769D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-20","https://doi.org/10
.1128/AAC.01325-20","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4585","141","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-21","https://doi.org/10
.1128/AAC.01325-21","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4586","142","HCMV","AD169","UL56","Q204R","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-22","https://doi.org/10
.1128/AAC.01325-22","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4587","143","HCMV","AD169","UL56","N232Y","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-23","https://doi.org/10
.1128/AAC.01325-23","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4588","144","HCMV","AD169","UL56","K258E","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-24","https://doi.org/10
.1128/AAC.01325-24","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4589","145","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-25","https://doi.org/10
.1128/AAC.01325-25","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4590","146","HCMV","AD169","UL56","F261L","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-26","https://doi.org/10
.1128/AAC.01325-26","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4591","147","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-27","https://doi.org/10
.1128/AAC.01325-27","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4592","148","HCMV","AD169","UL56","M329T","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-28","https://doi.org/10
.1128/AAC.01325-28","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4593","149","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-29","https://doi.org/10
.1128/AAC.01325-29","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4594","150","HCMV","AD169","UL56","E237D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-30","https://doi.org/10
.1128/AAC.01325-30","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4595","151","HCMV","AD169","UL89","N320H","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-31","https://doi.org/10
.1128/AAC.01325-31","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4596","152","HCMV","AD169","UL89","M359I","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-32","https://doi.org/10
.1128/AAC.01325-32","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4597","153","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-33","https://doi.org/10
.1128/AAC.01325-33","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4598","154","HCMV","AD169","UL89","N329S","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-34","https://doi.org/10
.1128/AAC.01325-34","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4599","155","HCMV","AD169","UL89","T350M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-35","https://doi.org/10
.1128/AAC.01325-35","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4600","156","HCMV","AD169","UL89","V362M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-36","https://doi.org/10
.1128/AAC.01325-36","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4601","157","HCMV","AD169","UL89","H389N","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-37","https://doi.org/10
.1128/AAC.01325-37","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4602","158","HCMV","AD169","UL89","N405D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-38","https://doi.org/10
.1128/AAC.01325-38","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4603","159","HCMV","AD169","UL89","I334V","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-39","https://doi.org/10
.1128/AAC.01325-39","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","N405D","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4604","160","HCMV","AD169","UL56","L208M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-40","https://doi.org/10
.1128/AAC.01325-40","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4605","161","HCMV","AD169","UL56","E407D","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-41","https://doi.org/10
.1128/AAC.01325-41","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4606","162","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-42","https://doi.org/10
.1128/AAC.01325-42","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4607","163","HCMV","AD169","UL56","V639M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-43","https://doi.org/10
.1128/AAC.01325-43","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4608","164","HCMV","AD169","UL56","H637Q","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-44","https://doi.org/10
.1128/AAC.01325-44","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V639M","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4609","165","HCMV","AD169","UL56","L764M","","Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","https://aac.asm.org/content/61/11/e01325-45","https://doi.org/10
.1128/AAC.01325-45","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4610","","","AD169","UL54","del981-982","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4611","166","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–105","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4612","","HCMV","AD169","UL56","L51M","","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4613","167","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–106","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4614","168","HCMV","AD169","UL56","V231A","Antiviral Research 163 (2019) 91–107","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4615","many","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–108","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4616","170","HCMV","MERLIN","UL56","N232Y","Antiviral Research 163 (2019) 91–109","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4617","171","HCMV","AD169","UL56","V236A","Antiviral Research 163 (2019) 91–110","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4618","172","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–111","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4619","many","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–112","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4620","174","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–113","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4621","175","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–114","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4622","176","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–115","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4623","177","HCMV","MERLIN","UL56","L254F","Antiviral Research 163 (2019) 91–116","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4624","178","HCMV","MERLIN","UL56","L257F","Antiviral Research 163 (2019) 91–117","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4625","179","HCMV","AD169","UL56","L257I","Antiviral Research 163 (2019) 91–118","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4626","180","HCMV","MERLIN","UL56","K258E","Antiviral Research 163 (2019) 91–119","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4627","181","HCMV","AD169","UL56","F261C","Antiviral Research 163 (2019) 91–120","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4628","182","HCMV","AD169","UL56","F261L","Antiviral Research 163 (2019) 91–121","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4629","183","HCMV","AD169","UL56","Y321C","Antiviral Research 163 (2019) 91–122","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4630","184","HCMV","AD169","UL56","C325F","Antiviral Research 163 (2019) 91–123","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4631","185","HCMV","AD169","UL56","C325R","Antiviral Research 163 (2019) 91–124","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4632","186","HCMV","AD169","UL56","C325Y","Antiviral Research 163 (2019) 91–125","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4633","187","HCMV","MERLIN","UL56","C325W","Antiviral Research 163 (2019) 91–126","New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4634","188","HCMV","MERLIN","UL56","L328V","Antiviral Research 163 (2019) 91–127","","","","SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4635","189","HCMV","AD169","UL56","M329T","Antiviral Research 163 (2019) 91–128","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4636","190","HCMV","AD169","UL56","A365S","Antiviral Research 163 (2019) 91–129","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4637","191","HCMV","MERLIN","UL56","N368D","Antiviral Research 163 (2019) 91–130","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4638","192","HCMV","AD169","UL56","V231L","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4639","192","HCMV","AD169","UL56","L241P","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4640","192","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4641","192","HCMV","AD169","UL56","R369G","Antiviral Research 163 (2019) 91–131","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4642","193","HCMV","AD169","UL56","R369M","Antiviral Research 163 (2019) 91–132","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4643","194","HCMV","AD169","UL56","R369S","Antiviral Research 163 (2019) 91–133","Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure","https://aac.asm.org/content/aac/58/1/610.full.pdf","","Recombinant BAC, fluorescence reduction assay","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4644","195","HCMV","AD169","UL56","C25F","Antiviral Research 163 (2019) 91–134","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V231L","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4645","196","HCMV","AD169","UL56","T244K","Antiviral Research 163 (2019) 91–135","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","F261L","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4646","197","HCMV","AD169","UL56","E237D","Antiviral Research 163 (2019) 91–136","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","T244K, F261L","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4647","198","HCMV","AD169","UL56","V236L","Antiviral Research 163 (2019) 91–137","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4648","199","HCMV","AD169","UL56","V236M","Antiviral Research 163 (2019) 91–138","Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","https://aac.asm.org/content/aac/59/10/6588.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L257I, M329T","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4649","200","HCMV","AD169","UL56","S229F","Antiviral Research 163 (2019) 91–139","A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","https://www.sciencedirect.com/science/article/pii/S0166354217306393","https://doi.org/10.1016/j.antiviral.2017.10.019","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","L254F, L257I","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4650","201","HCMV","MERLIN","UL89","N320H","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4651","202","HCMV","MERLIN","UL89","N329S","Antiviral Research 163 (2019) 91–136","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4652","203","HCMV","MERLIN","UL89","D344E","Antiviral Research 163 (2019) 91–137","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4653","204","HCMV","MERLIN","UL89","T350M","Antiviral Research 163 (2019) 91–135","Chou (2017a)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4654","205","HCMV","MERLIN","UL56","E237D","Antiviral Research 163 (2019) 91–137","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4655","206","HCMV","MERLIN","UL56","F261L","Antiviral Research 163 (2019) 91–138","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4656","207","HCMV","MERLIN","UL56","M329T","Antiviral Research 163 (2019) 91–139","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4657","208","HCMV","MERLIN","UL56","Q204R","Antiviral Research 163 (2019) 91–136","Chou (2017b)","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4658","209","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4659","210","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4660","211","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","V236M","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4661","212","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","R369M","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4662","213","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL56","S229F, L254F, L257I","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4663","214","HCMV","MERLIN","UL51","P91S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL89","D344E","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4664","215","HCMV","MERLIN","UL97","L337M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4665","216","HCMV","MERLIN","UL97","F342S","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4666","217","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance","https://academic.oup.com/jid/article/196/1/91/844651","https://doi.org/10.1086/518514","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4667","218","HCMV","AD169","UL97","K355del","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4668","219","HCMV","MERLIN","UL97","V356G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4669","220","HCMV","MERLIN","UL97","L397R","Antiviral Research 163 (2019) 91–136","","","","Marker Transfer, PRA","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4670","221","HCMV","MERLIN","UL97","T409M","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, Marker transfer","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4671","222","HCMV","MERLIN","UL97","H411L","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4672","223","HCMV","MERLIN","UL97","H411N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4673","224","HCMV","MERLIN","UL97","H411Y","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4674","225","HCMV","MERLIN","UL97","D456N","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4675","226","HCMV","MERLIN","UL97","V466G","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4676","227","HCMV","MERLIN","UL97","C480R","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4677","228","HCMV","#####","UL97","P521L","Antiviral Research 163 (2019) 91–136","Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance","https://aac.asm.org/content/aac/57/7/3375.full.pdf","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4678","229","HCMV","MERLIN","UL97","Y617del","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4679","230","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411L","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4680","231","HCMV","MERLIN","UL97","V353A","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4681","232","HCMV","MERLIN","AD169","E22*","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4682","233","HCMV","MERLIN","UL27","W153R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4683","234","HCMV","MERLIN","UL27","L193F","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4684","235","HCMV","MERLIN","UL27","C218del","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4685","236","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4686","237","HCMV","MERLIN","UL27","A269T","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4687","238","HCMV","MERLIN","UL27","del301-311","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4688","239","HCMV","MERLIN","UL27","L335P","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, #####","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4689","240","HCMV","MERLIN","UL27","V353E","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4690","241","HCMV","MERLIN","UL27","W362R","Antiviral Research 163 (2019) 91–136","Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir","https://aac.asm.org/content/53/1/81","DOI: 10.1128/AAC.01177-08","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4691","242","HCMV","MERLIN","UL27","W362*","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4692","243","HCMV","MERLIN","UL27","L426F","Antiviral Research 163 (2019) 91–136","","","","Recombinant BAC, SEAP","in vitro","strong","Tested","","","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4693","244","HCMV","MERLIN","UL27","A406V","Antiviral Research 163 (2019) 91–136","","","","#####","in vitro","strong","Tested","UL27","C415*","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4694","245","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4695","246","HCMV","MERLIN","UL27","R233S","Antiviral Research 163 (2019) 91–136","","","","Recombinant Virus, SEAP","in vitro","strong","Tested","UL97","S337M","17/11/2019","OJCharles","","","Cyclopropavir",NA
"4696","247","HCMV","MERLIN","UL54","G841G","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Cyclopropavir",NA
"4697","248","HCMV","MERLIN","UL54","K513N","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Cyclopropavir",NA
"4698","249","HCMV","MERLIN","UL97","H411H","https://doi.org/10.1016/j.antiviral.2019.104647","","","","","","","Hyp","","","19/11/2019","OJCharles","","U","Cyclopropavir",NA
"4699","250","HCMV","MERLIN","UL97","C670Y","","Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches","https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188","https://doi.org/10.1080/09273948.2019.1645188","Sequence Alignment","Anecdotal","weak","Hyp","","","19/11/2019","OJCharles","","","Cyclopropavir",NA
"4700","251","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4701","","HCMV","AD169","UL97","C592G","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4702","","HCMV","AD169","UL97","H411Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4703","252","HCMV","AD169","UL97","T409M","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4704","253","HCMV","AD169","UL97","K359E","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4705","254","HCMV","AD169","UL97","K359Q","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4706","255","HCMV","AD169","UL97","F342Y","","Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","https://www.sciencedirect.com/science/article/pii/S0166354219304115?via%3Dihub","https://doi.org/10.1016/j.antiviral.2019.104616","Recombinant BAC, SEAP","in vitro","strong","Tested","UL97","H411Y","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4707","257","HCMV","MERLIN","UL54","S290R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4708","258","HCMV","MERLIN","UL54","E303D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4709","259","HCMV","MERLIN","UL54","E303G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4710","260","HCMV","MERLIN","UL54","D413Y","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4711","261","HCMV","MERLIN","UL54","K488R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4712","262","HCMV","MERLIN","UL54","E951D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4713","263","HCMV","MERLIN","UL54","L516W","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4714","264","HCMV","MERLIN","UL54","V715A","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4715","265","HCMV","MERLIN","UL97","A674T","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4716","266","HCMV","MERLIN","UL97","L634Q","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4717","267","HCMV","MERLIN","UL97","Y617H","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4718","268","HCMV","MERLIN","UL97","M615V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4719","269","HCMV","MERLIN","UL97","D605E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4720","270","HCMV","MERLIN","UL97","T601M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4721","271","HCMV","MERLIN","UL97","L600I","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4722","272","HCMV","MERLIN","UL97","K599E","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4723","273","HCMV","MERLIN","UL97","K599R","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4724","274","HCMV","MERLIN","UL97","K957D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4725","275","HCMV","MERLIN","UL97","E596D","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4726","276","HCMV","MERLIN","UL97","A591V","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4727","277","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4728","278","HCMV","MERLIN","UL97","C603S","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4729","279","HCMV","MERLIN","UL97","596del","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4730","280","HCMV","MERLIN","UL97","del600-602","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4731","281","HCMV","MERLIN","UL97","C607F","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4732","282","HCMV","MERLIN","UL97","K355M","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4733","283","HCMV","MERLIN","UL97","V466G","","The Third International Consensus Guidelines on the Management of
Cytomegalovirus in Solid-organ Transplantation","https://www.ncbi.nlm.nih.gov/pubmed/29596116","doi: 10.1097/TP.0000000000002191.","","Reported","weak","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4734","","","Suscept","UL97","A594V","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Cyclopropavir",NA
"4735","","","Suscept","UL54","P522S","https://doi.org/10.1080/14656566.2019.1637418","Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.","https://www.ncbi.nlm.nih.gov/pubmed/14739146?dopt=Abstract","DOI: 10.1093/jac/dkh065","Sequence Alignment","Anecdotal","weak","hyp","","","","","","","Cyclopropavir",NA
"4736","","","AD169","UL56","V236M","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4737","","","AD169","UL56","D414N","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4738","","","AD169","UL56","S227I","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4739","","","AD169","UL56","R410G","https://doi.org/10.1080/14656566.2019.1637418","Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract",". doi: 10.1093/infdis/jiv352","Marker Transfer, GFP-fluorescence
reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4740","284","HCMV","MERLIN","UL56","E237G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","U","Cyclopropavir",NA
"4741","285","HCMV","MERLIN","Ul56","M31I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4742","286","HCMV","MERLIN","Ul56","M31V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4743","287","HCMV","MERLIN","Ul56","F41L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4744","288","HCMV","MERLIN","Ul56","L26P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4745","289","HCMV","MERLIN","Ul56","I48M","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4746","290","HCMV","MERLIN","Ul56","A103V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4747","291","HCMV","MERLIN","Ul56","E141*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4748","292","HCMV","MERLIN","Ul56","N148D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4749","293","HCMV","MERLIN","Ul56","E157G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4750","294","HCMV","MERLIN","Ul56","Q182K","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4751","295","HCMV","MERLIN","Ul56","Q213R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4752","296","HCMV","MERLIN","Ul56","S255L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4753","297","HCMV","MERLIN","Ul56","S269G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4754","298","HCMV","MERLIN","Ul56","E276G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4755","299","HCMV","MERLIN","Ul56","I313V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4756","300","HCMV","MERLIN","Ul56","C325W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4757","301","HCMV","MERLIN","Ul56","S378N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4758","302","HCMV","MERLIN","Ul56","S445N","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4759","303","HCMV","MERLIN","Ul56","E485G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4760","304","HCMV","MERLIN","Ul56","I535V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4761","305","HCMV","MERLIN","Ul56","E542DEL","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4762","306","HCMV","MERLIN","Ul56","Y575C","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4763","307","HCMV","MERLIN","Ul56","M641T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4764","308","HCMV","MERLIN","Ul56","L658S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4765","309","HCMV","MERLIN","Ul56","Y667H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4766","310","HCMV","MERLIN","Ul56","S705F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4767","311","HCMV","MERLIN","Ul56","V706A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4768","312","HCMV","MERLIN","Ul56","L750P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4769","313","HCMV","MERLIN","Ul56","Y757H","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4770","314","HCMV","MERLIN","Ul56","T775I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4771","315","HCMV","MERLIN","Ul56","R816W","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4772","316","HCMV","MERLIN","Ul56","P846L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4773","317","HCMV","MERLIN","UL89","K41E","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4774","318","HCMV","MERLIN","UL89","N74S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4775","319","HCMV","MERLIN","UL89","S102F","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4776","320","HCMV","MERLIN","UL89","F124L","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4777","321","HCMV","MERLIN","UL89","T132A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4778","322","HCMV","MERLIN","UL89","V146I","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4779","323","HCMV","MERLIN","UL89","P176S","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4780","324","HCMV","MERLIN","UL89","H243R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4781","325","HCMV","MERLIN","UL89","H246R","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4782","326","HCMV","MERLIN","UL89","D309G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4783","327","HCMV","MERLIN","UL89","L323P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4784","328","HCMV","MERLIN","UL89","T331A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4785","329","HCMV","MERLIN","UL89","S373G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4786","330","HCMV","MERLIN","UL89","M406V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4787","331","HCMV","MERLIN","UL89","N426D","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4788","332","HCMV","MERLIN","UL89","L458P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4789","333","HCMV","MERLIN","UL89","S521G","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4790","334","HCMV","MERLIN","UL89","L522P","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4791","335","HCMV","MERLIN","UL89","A532T","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4792","336","HCMV","MERLIN","UL89","I572V","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4793","337","HCMV","MERLIN","UL89","Q625*","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4794","338","HCMV","MERLIN","UL89","T637A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4795","339","HCMV","MERLIN","UL89","V656A","","In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products","https://www.sciencedirect.com/science/article/pii/S0166354219302128?via%3Dihub","https://doi.org/10.1080/14656566.2019.1637418","Sequence Alignment","Phase 3 trial anecdotal evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4796","","","AD169","UL54","V787A","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4797","340","HCMV","AD169","UL54","V787E","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4798","341","HCMV","AD169","UL54","V787K","","Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis","https://academic.oup.com/jid/article/220/8/1302/5519111","https://doi.org/10.1093/infdis/jiz298","Recombinant BAC, GLuc reporter–based assay","in vitro","strong","Tested","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4799","342","HCMV","MERLIN","UL54","L501F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4800","343","HCMV","MERLIN","UL54","A505T","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4801","344","HCMV","MERLIN","UL97","H469Y","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4802","345","HCMV","MERLIN","UL97","A590V ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4803","346","HCMV","MERLIN","UL54","D1129N","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4804","347","HCMV","MERLIN","UL54","V321I ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4805","348","HCMV","MERLIN","UL97","L609F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4806","349","HCMV","MERLIN","UL54","R1030C ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4807","350","HCMV","MERLIN","UL54","G1031A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4808","351","HCMV","MERLIN","UL54","L394F ","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4809","352","HCMV","MERLIN","UL54","E877K","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4810","353","HCMV","MERLIN","UL97","L609F","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4811","354","HCMV","MERLIN","UL54","T892A","","Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands","https://academic.oup.com/jac/article/74/8/2370/5489804","https://doi.org/10.1093/jac/dkz196","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","21/11/2019","OJCharles","","","Cyclopropavir",NA
"4812","355","HCMV","MERLIN","UL97","M460I","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","12"
"4813","356","HCMV","MERLIN","UL97","M460T","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","10"
"4814","357","HCMV","MERLIN","UL97","M460V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","4"
"4815","358","HCMV","MERLIN","UL97","H520Q","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","20"
"4816","359","HCMV","MERLIN","UL97","C592G","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","3.3"
"4817","360","HCMV","MERLIN","UL97","A594V","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","4.5"
"4818","361","HCMV","MERLIN","UL97","L595S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","1.3"
"4819","362","HCMV","MERLIN","UL97","C603R","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","8.4"
"4820","363","HCMV","MERLIN","UL97","C603S","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","2.8"
"4821","364","HCMV","MERLIN","UL97","C603W","","Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility","https://aac.asm.org/content/55/1/382","https://dx.doi.org/10.1128%2FAAC.01259-10","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir","4.6"
"4822","365","HCMV","AD169","UL54","D515Y","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4823","366","HCMV","AD169","UL54","L516P","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4824","","","AD169","UL54","del981-2","","Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection","https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135","https://doi.org/10.1111/ajt.15135","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4825","367","HCMV","MERLIN","UL54","L415N","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4826","368","HCMV","MERLIN","UL54","S734P","","Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial","https://academic.oup.com/cid/article/68/4/632/5049442","https://doi.org/10.1093/cid/ciy549","Sequence Alignment","anecdotal clinical evidence","weak","Hypothesised","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4827","369","HCMV","AD169","UL54","A543P","","New Locus of Drug Resistance in the Human Cytomegalovirus
UL56 Gene Revealed by In Vitro Exposure to Letermovir and
Ganciclovir","https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf","https://doi.org/10.1128/AAC
.00922-18","Recombinant BAC, SEAP","in vitro","strong","","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4828","","HCMV","AD169","UL54","S290R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4829","","","AD169","UL54","K426E","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4830","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4831","","","AD169","UL54","N495K","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","UL54","Q738R","","","","","Cyclopropavir",NA
"4832","","","AD169","UL54","T552N","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4833","","","AD169","UL54","Q783R","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4834","","","AD169","UL54","V798A","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4835","","","AD169","UL54","E951D","","Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/","doi: 10.1016/j.antiviral.2016.12.003","Recombinant BAC, SEAP","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4836","","","TOWNE","UL54","T419M","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4837","","","TOWNE","UL54","Q578H","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4838","","","TOWNE","UL54","L773V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4839","","","TOWNE","UL97","M460V","","Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","https://www.sciencedirect.com/science/article/pii/S138665320200046X?via%3Dihub","https://doi.org/10.1016/S1386-6532(02)00046-X","Drug induced lab mutant, CMV antigen ELISA ","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4840","not sure I trust this","HCMV","","UL97","T419M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","22/11/2019","OJCharles","","","Cyclopropavir",NA
"4841","","","","UL97","N68D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4842","","","","UL97","L126Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4843","","","","UL97","I244V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4844","","","","UL97","D329H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4845","","","","UL97","A427V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4846","","","","UL97","Q449K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4847","","","","UL97","V466M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4848","","","","UL97","H469Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4849","","","","UL97","A478V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4850","","","","UL97","N510S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4851","","","","UL97","M550I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4852","","","","UL97","A582V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4853","","","","UL97","H587Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4854","","","","UL97","A588V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4855","","","","UL97","A591V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4856","","","","UL97","N597D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4857","","","","UL97","K599R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4858","","","","UL97","L600I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4859","","","","UL97","D605E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4860","","","","UL97","M615V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4861","","","","UL97","Y617H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4862","","","","UL97","G623S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4863","","","","UL97","L634Q","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4864","","","","UL97","T659I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4865","","","","UL97","V665I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4866","","","","UL97","A674T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4867","","","Clinical Isolate","UL97","Q19E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4868","","","Clinical Isolate","UL97","T95S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4869","","","Clinical Isolate","UL97","S108N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4870","","","Clinical Isolate","UL97","R112C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4871","","","Clinical Isolate","UL97","R137C","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4872","","","Clinical Isolate","UL97","E227D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4873","","","Clinical Isolate","UL97","A582T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4874","","","","UL54","D515G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4875","","","","UL54","P522L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4876","","","","UL54","A692S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4877","","","","UL54","G971D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Transfer to control strain","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4878","","","Clinical Isolate","UL54","A15T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4879","","","Clinical Isolate","UL54","S24L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4880","","","Clinical Isolate","UL54","S32P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4881","","","Clinical Isolate","UL54","V95E","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4882","","","Clinical Isolate","UL54","H142Y","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4883","","","Clinical Isolate","UL54","G143S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4884","","","Clinical Isolate","UL54","I341T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4885","","","Clinical Isolate","UL54","N345S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4886","","","Clinical Isolate","UL54","G347D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4887","","","Clinical Isolate","UL54","V355A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4888","","","Clinical Isolate","UL54","S464F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4889","","","Clinical Isolate","UL54","A626V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4890","","","Clinical Isolate","UL54","P628L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4891","","","Clinical Isolate","UL54","G629S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4892","","","Clinical Isolate","UL54","A631G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4893","","","Clinical Isolate","UL54","S633F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4894","","","Clinical Isolate","UL54","M640R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4895","","","Clinical Isolate","UL54","S655L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4896","","","Clinical Isolate","UL54","S663N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4897","","","Clinical Isolate","UL54","F669L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4898","","","Clinical Isolate","UL54","S676G","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4899","","","Clinical Isolate","UL54","G678S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4900","","","Clinical Isolate","UL54","VSNDNHGA681Del 8","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4901","","","Clinical Isolate","UL54","N685S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4902","","","Clinical Isolate","UL54","A688V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4903","","","Clinical Isolate","UL54","T691A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4904","","","Clinical Isolate","UL54","A693T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4905","","","Clinical Isolate","UL54","S695T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4906","","","Clinical Isolate","UL54","Q697H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4907","","","Clinical Isolate","UL54","L737M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4908","","","Clinical Isolate","UL54","V759M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4909","","","Clinical Isolate","UL54","Q868R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4910","","","Clinical Isolate","UL54","D870H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4911","","","Clinical Isolate","UL54","V873L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4912","","","Clinical Isolate","UL54","G874R","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4913","","","Clinical Isolate","UL54","S884Insert T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4914","","","Clinical Isolate","UL54","A885S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4915","","","Clinical Isolate","UL54","A885T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4916","","","Clinical Isolate","UL54","P887S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4917","","","Clinical Isolate","UL54","L890F","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4918","","","Clinical Isolate","UL54","T892I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4919","","","Clinical Isolate","UL54","S897L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4920","","","Clinical Isolate","UL54","N898D","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4921","","","Clinical Isolate","UL54","E899K","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4922","","","Clinical Isolate","UL54","V927M","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4923","","","Clinical Isolate","UL54","V953A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4924","","","Clinical Isolate","UL54","A1012V","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4925","","","Clinical Isolate","UL54","L1020I","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4926","","","Clinical Isolate","UL54","T1108A","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4927","","","Clinical Isolate","UL54","N1116H","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4928","","","Clinical Isolate","UL54","A1122T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4929","","","Clinical Isolate","UL54","G1133S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4930","","","Clinical Isolate","UL54","S1146N","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4931","","","Clinical Isolate","UL54","N1147S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4932","","","Clinical Isolate","UL54","R1149T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4933","","","Clinical Isolate","UL54","G1151Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4934","","","Clinical Isolate","UL54","P1153S","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4935","","","Clinical Isolate","UL54","A1154P","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4936","","","Clinical Isolate","UL54","K1156Del","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4937","","","Clinical Isolate","UL54","P1162L","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4938","","","Clinical Isolate","UL54","S1235T","","Antiviral Drug Resistance of Human Cytomegalovirus","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/","doi: 10.1128/CMR.00009-10","Clinical isolate","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4939","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4940","","","Clinical Isolate","UL97","H469Y","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
"4941","","","Clinical Isolate","UL97","C603W","","High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes","https://academic.oup.com/jid/article/176/1/69/901024","https://doi.org/10.1086/514041","Plaque reduction assay","in vitro","strong","Tested","","","","","","","Cyclopropavir",NA
